var title_f29_60_30656="Barretts high grade methyl blue";
var content_f29_60_30656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chromoendoscopy of Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 327px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFHATgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WooooAPzpQOCcj8qAMjNfQf7NnwebxBdw+KPFVtIui25D2du4K/a5AQQxBHzRjnoeT7ZyAdN+zJ8HkhjtfGXim3Vpm+fTbOVAQg7TuD3z90duD6Y+mTnPBP5mlPOPbA4ooATnuT+ZpefU/mf8aSgnHXpQAEn1P5n/GjJ9T+Z/wAagkuYkbBNVZdTiQn/ABpqLZpGlKWyNH5v7x/M0uT6t/30f8ay11SJu+PxpkusQxqSW7etVyMr6vU7GuSQPvH8zUUkqouS/wCp/wAa5m78TQorAH/x6sm78UQ4Pzf+PVSp9zWGEnf3jqb++VAPm/PNc3f6kBIAH7f1rnNQ8TRSD72Mf7Vc3feIYyxIbt/eqrqOh2woxpqx2U+pKS2W54wc1Rn1gLkbuc9q4K68Qpzl/wDx6se58SRhvvYAPXdWkKiRhWSezO7vtYBDBH6iufutVcZyTg1yMviSEn7w/wC+qqTeIYGU4bP412e0izzHdHWPrZUD5mGD24ph8RHdgs2T7n/GuFu9dhb7n86xbvXAG4J/Os5TikCbPS5teBY/P+p/xqq+vIzH5zkf59a8mudbdmwpY++ahXV3LEZYf8CrnlNM1U2j1iTXkB+++PY//XqpJ4jQA5dsY/z3rzI6u2SMsce9UpdTd84JH49az50hym2epT+Ik2feP4H/AOvVKbxFk8OcD3/+vXnQvS6DkjPXmkNx2yT+NJzRPMz0OPxBuI+dv8/jWtaaukmAxY98n/8AXXlEdx8wwTge9XbXVHjckk8dOaLpgptHslrcrIRtPH4/41ejkGTxnHpmvNNI14MVyefTNdVa6qrqRyD9etOyZammdKkoAwSah1G3ttSspLW7jWWGRdrZHIHqM9/5Vjm/7ZP51Pb3e4Y5/A0WG0eK+MfDsvh3VDAxL2z/ADQykY3D/GsA19D6zpdprlg9rfRkhiCrr95WwQGHvyfwJrwnXtJudF1OayvUMckZ47hh2IPf61lJWMmjOoooqRBRRRQAUCgV3Xwg+Hl78RPFcWnwFotOhZXvrlf+WUXPQ4I3HBAyMZoA6H4B/Cib4g6ubzUVeHw5ZuPPk6G4bIxCnIIJGct2+tfclpbwWlpDbWUKQW0KqkUca4VFA4AHQelUfDWhaf4a0G00fR4FhsbVNiKABu7ljwMljyT61p96ACkJx1IqKadIwdxFYWraqwQiNgBjrgVSi2bUqEqrsjXvNQhtlO5gW9K5++18sMIVAz71zl9eO7HL8ZrGurwID81Dsj3cNlUEuaRu3mtPnhhWbca027BYdK5i91AAHLVg32srGSTIMioc2el7OjSidnN4jdCRuA5rD1LxVJtPzkD61wWp+IghYq+cN0wK5a71iacEIzYPSqipHBXr01seg3/ivarEyjp6muevvGMpzsZT9c/41xz+bLyx5HvRJ5UQ/wDr1pZ9Ty6uL10NybxLcSdwv1zWVc69ctIFV15HvWHe3mMBTgjotQyvADbuk7O7f6xfLI20mjllXbZen1ubewZsn8apy6lNISfNwM8CqVztaZjGSUz1NRhcde1Tcycm9Sdp5OfnPSq8lzLt+8cChmOCRzx0qu+T06UXZNiU3EgG4Nz0xSPKzdTnP6VC2QB9aUkqOKV2ISQFT940fUmkb5l96cR0B60mA0MQx6U3b8vSpANxwRTVTK0rANJwgx2pdx+97050/hz05JpMYwM4oARSQD6UoZtvOOaVU3/hQVYHHagY+Cd4myrEH3rdsNbkjA3suemea54L8xJ5FB5HtniqUmI9AtdfSUDfgE+ldPpN1HMoYMAR6d68bSR0RCpP0ra0rW5rVlG4dfQVSmPmZ7VbtuQ9OtZnjHw3D4k0vyyUS+T5oZWH/jn41l6J4iiuIwrsA+eldTb3SuFKMOh5Bq90O585X9nPY3ctrdxtHcRNtdG6qar17h4+8JJ4gtGvbFQNTgTOOiyr3BPr6V4hIrI7KwKspwQeoNZyi0SJRRRUgb/gjwnq3jLX4NJ0O2ea4kOWfHyRKASWY9AOO/U8d6/QD4feDdL8DeGLbR9JiGI1xPOQQ1w+PmY5JIyedvQZ4rA+Cnw2tPh14Y+z/JPrNyQ97cgAbjzhF4ztUEcHvk967y6uUtoyz8+g700ruw4pydkTswAJbp61l32rxW+QCevWsPWNXlkO1DxWBdzdSTWypcquz1MLl3PrM07rWGmc/Nx6ZrJ1G/Hl/NnGKzLq/SNDh+xrmr2/Zmz6VLbex7MadKia2oaoqA4z1rmNT1wRjknOTWfqmogI3IJz61yep3XmsMnFJQvuY1sckrRNPUteZ2OwnGMda5fUtSkkc8ktgd/am3Eny8cmqbDc3fPpirUEeRWxc5dSFmZzufknnmm5CKozxUzAJliQD6ZqnK+8Z6e9O1jjlNsJptidwRWdd3JY43Nz70l1JgbQOvU+tQfdHPepkyGQn7oOMlT19KYCxl55Hr6VJKvSmEcjAqGIVMEsM5o/hPOTTWOMjgVGh4PWpARstkkmmsv7vjj3FS9Ad1RNypoAbKRsHAyDTWbnjkHvT3BIFMIyck4xSAQA7gCcZ7VJwDjB9aaTlW4waaM5z+ooEOd9xO0gU3cQOCRS5GehPvSHO08ZpDFjUEYJJBqTywWBAOfeo04Bz6d+1O/CmFiVflBPvTWGUY0z+IU3q5xQAAdaT7vXpTh1NCjGWwaQhgHAoIGDTtvFGD6H8qY7E9teTW5Db25PHNdx4Z8SkFY5izA8ZJzivP2HQEH8qejtC6sDjFUpWEz6BsLvdtcZwB+dcR8T/CovI21jTIQLhMfaI1HMgxgMo9QAMj8a3fhzejUbUQsQWVfX2Fdglowd8dhg59PSui3OrEXsfLFFelfE/wAESafNJq+mRZsnO6eNRzC3c/Qn0orCUGmWmfbkmqpbW+5my3dj3rA1LWFnCtvwvrWNf3Y/szzWfPUDmuY+3NyHfINeg6UYbbnp0FCDub13qo8wgGsnUdV/dvhu/wCVY9zeYLEnFYd/qQMn3jweOK53BtnfLFRiXbnUflOT2rDu9T3Ky7uCKpXN20pYMSB69qzJ5yflXP1qlCx5lTFSl1GX90znhsjNZcgeQ5GcVo+UXYFyCPQUy5ZIUI45o5TklUbKLRYALGq00yoSBy2KWeV3PBAFUZ5FRz1JwKlkXGOx5aQ4JqrK+5MDpSzyGRuhC1AxGOlZtgRSDMgNNb5QcdD61I3Iz6Ux13DvUthYgYZUcHNMIIGOlWXQYGOvvUT8vlhx04qWMrMMnI5owdo9c1MyruwKURE9Cv51IiuwJ6U0jC59KtLEMd6RojjAxjvmiwyochflOeaRsAcZJ71a8jJ74/SneVtbGBn1osFimUYjoRx1pCuABV9ot4K8evHeop48AZ2gDpg0WAqquBx3pwXgjtipoYXmbEeOPXpU4sJFQuTlMdqLBYoBDjJHFB46dKsGMq3IIWgxjHSiwWIApwMDNOKZPT8qm2jOORigLnsc0gsQYJzmnKMqQOtWTAB14o2EKdoHXFFhrQrbWxnHP6UpAAB5z71Y8ltvbb9abs4IAzTsBXxk4/Q0yfKoflJ9M1qW9ou0NOQCemKS4aPcECcE45FCCx7p8M/Bul6T8NLjxBqGoGPVPL81Yd/AHGBwOSeasaJrkeoxidwImb+HFeOQ6pdiNLRrmU2gAwmeK6a3kltbRLqOVQqkZXPP5V10lFLQwnc9elt4bm0kjdBJFICGB5B/CisDwhryXkCpI2c8UV0cplzJbl671V2RI9/yfWqE98BnnI+tYE95lwA2Biqr3TSdWAxWslqd/trGrdaiSG5z261kzTE/vAep7mombA5PFVyQ7ENwM5yKzsjOVVy3EmkZ8xjjHUUJHsjBfj1p42ohDEAgEg96yby8ZyAp49qh6EczLk95hwqgAdOtZ95OMlSc571VmmbcAO/U1HLGUVWZhtPasZS7Br1EMrMACMDtVK4OZOmeKtlCYuCPUZqjIfnxnkVm7lIi3Dk8/nTQPxzQeCc4GDShWIHAI9qlghHUjjoKQDg81NtIXgc+9MKHk560mVuROAMHk/jTHQt3qz5TFckcU9YCV+bg+1SNIprGCeOvrUgix1I+oFXorRiCfWpBZDaCzn6U7CsUhHnIC/jSNEQPu5rctdOzHuGal/s0kE5OafKx6HPLCQMt0+lMkUZBI4HU1vPZFCA3rimy6bE2FkkChvQjNHKwdjn9rTnZAhPuKuxaUcjzmy3pjpXSW+nx28ICqyj0I+Y+9Sz2Rhi84n5OvPWqUCXoc8ljgbEXHqQKjmvEiUxxgPnjPQflV65vy7+VbACPPLkfMay2hG9uBwM5qlAm9ytNIXBG0YPU1CYyAGx8tXCileQCPelkVX25PT0pOA7lfYhXdjPpUsafKqlcjrS7BkBc4FXLWAh88sPelygnqVpbZ2P3SBUZtm2HAwAeprTmm2SFQAzd/SozJuVgRkZ6UWsUZ5iAXG6kCAD5Rlqux2pdSVyAODmgwgYA7d6LICgQSRuBOO1NdOQx/KtOaJYxn8ie9QQWrXk4DkxQjl2qeUeliGFWJDgE4HWvU/htZadrMU7atu+zhSgAfG0+tef3TwALFajbEo5bu3vXWfDGJL3VzBNO8Nmf9YYyAT+eRWkNGZyKonGj+MLm3tHzZo5Eb56rk44+mKK3PiTpNjZaoF0slo1/jONx+uKK7E9DNxTMN7gvNu3dfapRIFLDvWazBHUDrVqHCJ5khJ47803LUbLXzPGSeB6UyefYBu5+lVJ78BcJkD1qjJdtKSN5JHoahyEEt08zMd3SoAWYbgcE96QgKT0z6UsYwhDZIbpisXIpImsPJfV4Fuzi03fvOccfWtDXDpX9puNFike0Tuzs2T9SawZwT0Oee/WtWxv/ALBpc8KW8EpmPEkiZKf7p7VAzOv2OQQoQY6CqMoy57cCpuSnz5LdzUaoXk6fnUsaI1jDseCSKfHGdw45q/BAM7SBU8FrggsMt70ikU1gODxQtuBnjvWkyKrDcTj0FMkkjVCqqA5745pWL2K8NsCQMEg/pU7WbGUbADkU6xmCsAwJ9SeavW0yvNtjX5jwCOKpQFzDIrFhkP0AzSwWatNudCVB9TW/HZJ5BLSNv7hjmoUIjcxgD72KtRJZSVXThe/HSgQO+c5BFaCgJcbCp6d6eY9qsxOAe9Uo3E3YwrtkhcKRznk9ahmnhiBZFBZh1PP/AOqk1TJmJRt4zjmqaRjzMsFVR1A71SgS35mx4Zdp5mVo3kJ/iYmulTTQH3OhkTsCeK5vTNSWxgeKJcMeQR2q9J4nkitiis7SHuScVryKxDkzM8X6OLaVb63CLHn5ow3P5VzpbdGCmCCOcitS8vJrydmn5J555rPaLA4AFZyilsWndFNwMDFPEO5wNvbrU3kk84zVlcfLtHbvU2AgWJUI+XipihLbuQAOgq5Das8ihlBz2rSeyVIQpRQx56UmrMqJzQDNKQseM9utTW1vuJG0k9wTjmtmO0VMkhA305qGRdrHBG4HJqbFXKyorKc8DBqCWMIv3gBVh9207s4x0FZ0pilSRbgzKw+6FOM896OUm5WurzzCFXgLTXdtgAY7fSq7IGzgOuD371KzkhQBxRYRGSSx54xW54YvJLaffG20njgVjrGCwA5B4/GtSwhKS7RwfahIDt5pVntWaQ7iw6mis2Fm8iNSTnpj1orojsRJ2ZlR4Vw5AHtnrUM0xC7jhRjpmlYFAGbtVGQtMzDGeazctRj94c89MU+MDeSoA571Hs2pgjmtXw8ltJcO16ryQxjOyJ/LY/iahsZQDAEhlDDByuefyqJgNmRkJ6dxXWmx0rxLpM03hbStSg1G1yZXubtHjIHPCnHp2rjHmLB0c/vBwSOxqQsPIzIo3ZPocDFSXiOdvKgD3qG2j825hDSLEjsFeVgSEHqQOfyrS8T2UFldxRadqUOqQbctcQxui59MOAf0qbDSMY7ydmAxPatrT9OIVCB8xp2h6U006zOp2D17119vZopyF+b09KC7GXbaa0aZK5zyRUV75VvEoMqn2yK6Z7N2UgfKfWsLVNB8rBklBFXGNyWzmJ8yyttQ808WwEWWyp7CtRrVFxjIYUkkA456np6VooWFczY4WWHOOfQVpaTJJE2YR8x6k054kVVA5NS2trK7japUH6c1dgujceVRDuJUSYGRnrWVcXgMuY+gPIqaW3cZVm+YYqrcQqOAMtnqP61XILmKcupSGQOgIPcEc0k17JNFiTkGq0gJlY/weuKkgtyFZnO4N0qkrbEvUCEMa4UDHPBpGV32sPunpxVi2tyD852g+ozU8kWCAvyx/wB6na4tEZsilQRtIbHequM5BP51rXAjBGSSQOvrVJjGSeOfSk42He5UVVdm3cfXimhCeI935VcaP5iyjA75qWO16MDgZqWikUxbududqqTyc9K2LO1RFBB2qTjnuaVIY4jksrgckelOQmSZGl/dqp4X1pIZp2oWAMxKg9gTjNU1mDXDxy4Abnk4xUN+BcyeYrlUX0PeoorbNwsty5KVEzSKLEiQor+Y/wAueNpzVVoVYnyRyDjmrUq+bJwFEY4VdvJp6WchJUrsJ56is0UYOsBPs/leYenbmuclcspiQbV6EjnNb+tJHDGYYHMrjq2CMfnWVaxRJkyHD1fKZMqLEqQrv3deFxTlyc549Fq3dMkcpZjn0FQwIzneVwM0rCJrSJfMXIycdPStSNNx8pMbSQWNQWMJMhYj8a1NMjDTPzwKmQ46s0LXbsUYwBxRShcOB2Jx9aKtMpx1OdvXLbUGevemJHhSwPWnYLzZHQE55p7HC8Cok9SLDGUBP60yyNot7G175zQK2XEYBJ/DIpzA4yOnpUAiZpmAGFJ69c1FylG5tatqH265L6a0lvaqMBcY3fXrWVHBvDBVz7mtO1tswkKmDj1rS0zT1FuQVy1OwJGJDa7EywGKt2VibuUDHyDnNactn5jLHAu5yeR7VvW9jHZWgeUrGB1Y01EbKzRLbwRRx8c44Fb1rDHDCM43d81yr317qd19m0C1aeUfKZn+RE9/mAz+Brr7DTf7PsJDqE4ublh8zKNoH0GTWns+5DkwnJMZZAgXP32OBXNy25N080rswx0NWZ5mRfJtZMQ56N81UXuOODnjua3hSsZykVrthEcjv0rNkd33Efe7Yq+IWupyOpH4CnLbxtIY1BJXuKvkuLnK+nW0kzKzIfr61tQoYWLcBcYqW1tntYdxYH14qOVJHAYthSPSjlsNO5UmlDOxDHPvVSMTySBIozM7HgIMkVelhjbbF8oZiMEnBru9G0trLSoPslur3DMBvxgmqjETdmcAPDeoxMZfLSRXGSsZLBR3zxxTY9O8p9rDjvivQvEksKRBVlKgDEiodufyrkLvYIWYkoT93POafIClcyXXy32rjHvVe6dvLKquTVznyyWAwTgNURgdiPKOW9SOBS5RsoraGRMse3INNltFAwo2n3rXzsjKyrtb19aiMLkbnGf7vPNKSAzTCYky4BB7U5Y22r5a5Q+lW5I23Y4JB5BNTWkLrC5JUAdKixoQpaqkYkKBT7HmllVd6BzK6dgFGM+9W1iZ8g9cZDdhTormJISFwwX71TIaV2VZI41aNFjUk87c8Uxx5UvzDA6gClw1y+9UKJn71Om2T7RHnCDkk5yays2a8yjoLJIsYEka5I/vcYqr58jhyu4uTxTnt5pUO3AC8k1V8hoxujdsn261pGmZSnqY99u8mTLgnriqcMCy5e4JWIDqK3bmOKJg5IORkrjrVE27zAuI9kHcE9arlIuZMFu13MWHEQOMtxW5HbI2yKMHP0qa2tRJHtRQqfzre03TxbL5sxDZHHGKzmrIqN2ZSWjRJ049qtaXZlA0hHA/OrsiLLMCvI6YFXzB5cexBjPWueT0OqNMzbiMCIyY4BoqfVB5UABHWitYK6JnozilBeV5EUAMxbaOlSxwFwd2QAO3rVy1teV/WtA2fGAKys2YXRixW7SERqpJJ61s2+meUi+YDnFaGm2qHjbl1PrWlLbKjrLMCfYGqUB8xm21jsVnk+RQOnep4UUISud3YDqaUMZpfmyCOgrSsLMopdxulPQ+n4VfKFyTQrELMcjMjevata78P21/Ki3qtNCDkxNgo314q1penNEnmOfnPU1uRosUfmNye9CT6A2UZLWK1tY7eJY4rZRgRqPlUegrnNf1e2S3NpAN7HuTmpfEXiLzg1vbwhGUYyec1y1lays7PdjGTmt6dJ7sxnNW0GYj+zyHzCHJyAe1U1RsDHLH1rXkijZiCM5PHFU5VCjCjArqjExbGFTvVQSGxjAq9FbbCsjfKX4wO9RWyRdGDDPfJNbYgzbxsozjpmnyhcjggkkjMZOfZeg+tOmsy0IjQnCj8a1oYQum4hGJ3PP0rOvJzABHD8rAc55/nUOOpopWLPgvTdIN3cTa40XmxD9wsh7/AJVo6l4j+yFobUx4J4YZwPpXKTbpHDZO5etXLaNZ0AdeQOpq1GxLd9yK8k8+IlWEkh5INUjEzpsk3evPar/leSScjp6VXYlQzMp3HpzSs2CaRRdVaRUB4zjA6VaaBg6KibY+c0+G2UEMVJHXI7VfcecAiPzjrihxsLmMaaMO5XkgdzUc08dsUBRnkfCJgZJbtV+4iMasF5IHPua7X4faTpVpZtresyxySxk+TCTyvPpnn8RUSWhSkluc1o/w217UlW5vVS18w7hF8wfB6HGCKzJdOihuZLXfvMXVieCK9C1zxbPqMcsNn/o1u5OZDyWGffp+FcNEqfZ596n94D82eelQ46amqnfYoXkkdvGVRipIAx2NV7S1WQ7mURxfeJPep0hSVMOpZlPBPGRVo27EBVHA7H0qOW5oyg++4bbH+7jU4wvcVLJaRKgjXKrjPy9Sa0TCWAGAGxgEU62s2diAN20etUrLQlKUjMSIPGQIyoToPX60iW48tpJ8RAHgVsWlg9xOfPyEXsDinXlvG8u5lGyM7efapdaKdi1Qm9bHLtZLNi4ESrAnTd1Jqr9la5ugjjanoK6+azbyQSgZMHGO1Z5s2ib9yu6U9e/H0rP2qF7J9TMWyEZwM+XnvWlcIUtF28oeB6micOV5Qll/hq/ptnvtjPcgjj5U9Kib0LhG2xn2kJDoWXBrQK+ZcdPlHWizi8wuWB2DjninIxEjcbVrmmzupQvqzF1475sDoCaKTUxl3OeSTiiuqmvdOStbmK0VsUdflGO5xVna0hAjAKActjmql5NBNNHC0yDB5BcDNT3t4rxpbw4ESrgyZ5PtWsaa6nFz6iaRcAXsscfznOM10M0ZChpMk+9cnFa+Shnhm2kHhBgk/hSzXcxJZTkk9O4oSSZV2zotOhjuLktkkL/BWpBLbRXarJL83oa4rS4ZhISCFB6r7VtLuMYVMAe9CimF33O2lv7aKIkzMenArLvdecJmJ2RB0w2DXNSQLJcK+394PSrsaeYfmIz3NaxgkZuTsUhC89w082G3HcCeTT7mQEHYx+XA9qt3M3lWpSJQQeDWfFHtXbGrBicgkVqiGP3MIwihzK3oetM+xSsiswxWg0G1AyABjy31qRbT7RExcEov6H3rRIVxttaKsIWNFZj1OOlXInZ7sQKwLdk9KbaxlUZpWV41HAzUdrDLqF4xQJ5St2OcVVhatkzXLx6j5SkxFOWI4qm5Z7iUldwJzuNTaqQL5UVCxUYLd/ypVhldWERIUDkkYJqba3K2K8KkMSO/WrdkgLlgTgHp2NTQwusabgWA/iIx+dSXBeBfMVNids8E1VhXKl4gllVEG09aqyDahExYY6FiP0qa0jmuQZmwkT9Md/r6Vo2NgtzcfIQVUfMynIFLZAtSlYwMLbhWKs2BUjqiyqqoqsOuRV24nhmvAiEFYyBuB+UfjUV4VSfKFXLDscg1k5XNVDQzplQXJ8hWJxz5nIPuKvbYLeF5yVjJGCHHBPt71WTeZjhcg8YqTUoP3SLM2BkEoOTWfNYtU11Kce6Yk5dFzwkhzn6Uy9by2CkYfuD91anknFuxfoCPlz1NTaVZOZUlkjXJH8RxSepfw7DIbAyW63MjoT/dApWSPB2OA3RQe9amqssluJpo1KxDGAeTz7VoXWjX0Om2mo33lrbXQxbrn5x3+YdQOKwqT5NDenDmeph6Tp008waZScdV7Va8hRebLVcH+IDituztVSHDDbMwwoH3T+NaNnA9ujQq6MTydpBxXHOq5M9GlQjDcxYoEWB9qKGPfHSqUtkkdu73CrIGPC4zWvOFLy+ep8pOvuazLlI5SfKLKO3FKEWy5yUUZE84gsiYsuAOM9qZpayMjTvECz8CQjlfxqzcWJj08yOfkznB4NWrOFNiykGZ2GA45CCupxtG55rlzysUPspSXBG6RjkZ6mryxM2FYKhA5AHNaFpbMsqmIebnqw5xT5ok8uVvlVlzls1g5vY6IUlucsA0lw6JlVU4OO9MvHVSqL+NX40/dytnGQcH1Nc6zYuGX361UafOKdVw2Kt6oaVsdiePSii7Gxmxyx6UV1xgkjilO7uYOq2DG4Eq1NbAKg3tk+laeoQ740cAk88D+tUAMj5hgd/WibdznjHqSQnJOe1TrApZpHBGT0qruOSoFW7cyTKEPCjiktSti1YDBMhxsIq2q+YOPu1XjlPlMoGMdKtWy4VACCW6+laxRN0KFJY7XCHpzV2GORgmUwPUd6fa2i3RcLkbOSTwKtzbRAFGdw9KtIi+hmXETSuYywx7VLCjM4Tg7RjNSC0wgO752OefSrjJ5SgIhPH3sVtFEMqLGIC7SSBvVfSo7KW4eOU+WTn+EcbquramYmVkbPYEfeqWEM0T5+UL7VWwrXKiK0UTTAgqB9w8jPpiqmmzPBci62mMyN93PH5VfjY/ahkhR/OkniitLvfOrkyfd8sA/wA6a1E0+g3UI3kvftIGI1G5mHer1nmcedMRFHj5Vznefw6fjUVwuLZFh2B5T2POP9r0/CpIYFiKCQKpAzvz1+lVohakhcSRuJhtbOQB+lQzQSX0q+a+2ND0HamTXE32ggRhozj945wT+VX7TJuGEQTy8fOCfm/Kpukxxi+hUayNzAWiJghjPLdj+FSLdGKLyYlCpj5nX+IVO0yRxNHIHmhOT846VmFtiu0KuY2+9kfd+lYydzenDuSSGCTLBfLgUfKo6k+pqGNZZmzHtEQ6kikjVi0a23XPO7+vtV2GJo5lBLAnJYfw/hWN7GluwtsqW7Z2ZU87zVdisdyzhgw65cZA/Cpp5m3E48uMjAHrVfaJitqGVY2OcscE0rJl7LUrWcbXuou7MsiliAAuFT8DXU+QgiWCJlEyc8g8j61Da2sNpZrbrFKJ3PDFenv16VvW0awyq8vl7gpxtOSaicklozWFJzd2U4tNSe/imkAMar80Z6dKnvHF/d5uJD9mgGIoh0pTeILK5hMCtIf+W4++oz0H8qoteKlhHHBFumJ+839a5lBzep1cyp6CxySSbrkL+7Q7REOoq156rAApy0vJUDlRSWKOuwhMoR8+PWmGNorqUJGrhlwWbOVHtVuikKNZt6FGeKS6y28pBHwQed1Z10GRD5TYfsDWhE0iNtSaRPmwExT9Yi+yWhmvVzMxyrJyRRGNhTd9ym6B7SBADsI53c5qCNZF3xKcZ/u9MVZ1GZrLTY44VMonGeR93NWdMtPsVqtzcoNz84HJP51o9tTlv0Q+0kayRWI/dk4Jz0pmvWgFuJLdiVk5OKXTP3rTXEqFoy2RG1JeTmdAqAKingHr9K5Z2udtJSS1Zz05aKLy8HG3jPpXOyZ+0OcjP8q6fUjucjrlfyrm7mIxS7RyT1rsorTU5K71KZDb9zfN60VMV2htp564NFb8pzXOs8MWvhlNHurjX5nk1Ug/ZrdAygH1LDIPbtXKy6dM8TSyqFOTtAHatOJgoRAefYmtJiohUMAB9Ky0uQpNHCJEWmYOpXH61qRJ5UY2gEduf1qbVwk0qiABdvp3qvta2+Z/TgVUYicrsjlXYGyME+9WtEjLZllJIHAWqsETT/NL93qAK27C2whldtqKKtIi5caVUBVWw+RyO9W4IsxF3H0HrUNpbIZTITuJ6CtGE4JLKAB09qtIXQgEBcqeAP5VYkjDKVDDaBTIgBI7ueP61JqKj7Evk483OcVuo6Gbkyt5qJCI2LD05xgVE7tsB2kD653VGllcuJZpWDD09PpUiwzy28UwIjSM8Bup+tDiXew9IlPzumRj6Gqty5+0xuRsROhY55qzqF8IRGRGCTw2Ac/UVQv7S7jvYUuBtgl+dCRS2HuXbGZ7lLhXCoGPpyR7elQ3EBhiVYQzHphnzg1Z0+J3LiNQ0gyp/uqKmSyyi+cwwO69T7GjmtuCjdkVrbSSRLLL/D78cVfhYSF3GIyvOAu4mgWzuPKZjGvVR/hV60iitrGdpCPtK8KD1NYzld6HVTgZYZcF3XJxk88GqDmZLjbAVZG5IH8NTuJPILkAAgjB71b060EELXJQ+Yw+6egFRfQrksLMkUVsqxx+XMeXnzkEem3/AOvVcRl1Ak3KeSG65FXRameMt5jFB825O31zTZZysYgiVHB6sB1rLl1LWiM+0UXM7qwKGP7u7kGtTw/pub83U8RcIRsTHf1zV7QNKklZ1uSyo3+rxwSa6LS4XtUuIPM5HJP8QH16UTlbYIRctyGcG31I3sAVriRACGGVH0FYgumiEqbNxbnJP3fpxVy4v2F8fKCshYj5/vfpWHK80l1IyKBz0/hFRCjzu7N6lb2ash8F09sZZlUMrdQTin6fa/ZnN3ct+5c/KO4JqSdIba3Et7GkgcYCx561RvruUPapHBGxdh5YAOVHr1612+yUVocPtJSdzeVJ52Zrf5Ldecngn8KpXksVza7ULxyA8yZP8q19ItrhLvNy28yLyJPvVz+obo9Se2hlMhJz8v3QM1yyaudcVK1yWd4oUBB3kLyxGOaw21GWe5HmZMQzyx3Ct68WM2bwSupbjJHaseJY41IjCzRqMHNOFmZzTW4LIk8KImTtOVXdnNaVzPJNaeTK2Ni/KKm8DabaXFwWvXeKBh95cbh9MirV1bL9tvSqg2cfEbt95v6fpWVRtaIqiosq6Criw6ZBbqeaS4VVdtoG3nLU1rlrbSyIwMMcL1z3pBvGnB3Ay1c7i2dkJWWpz95uaQ4GM8A1lyxgF93L/wD1q2bvCKH5xj9axnkd5y5UbeldlNWRxVndmXMvLEjBzwetFXWRTK2SAo70VrdmHKiSyaI3COXXLnGPWtHW5PLtlBU4PTFctootoLmKSZ3eYfcGflX8K37q5nuNnmriI85PQ1Kj1OZy1MhlELeaFbJA6805Wa4R2CkY7mrssgmlWNdp7dKRI9kpjzx3Y9BWiFcZYxqYlAHKnitc2m5FDHAPJAqjAFgXJHXjNbFr+8jIY4XHJ9KEhkgCog8o8IKqrcvI37xiq9kA6/jVqJAc+Wcr3JpwgUvnav8AvEc1d7DtcfaTo8bkBmkA4XbxWjYwK6MxQLKVyVDbvpWbGxiPy5Veh9DWnoe59QklETvEExgHjp6VabaJasS6NBF9jne55UMTtJ5rMaCS5mnnLExjhIgOlXZblIf3ahpZ5W+WMHoKn08/Y3UyDYd2GZu4q0rGTZnvpSC0O9Q0jAZBJ+UZp9/aRmwjSJzLInKE/wDLP/H8a39Zs1lUSQboFK7ty8K/1x1qgAq2YlHl4J6qMEmk1dXNISu7GVp8JGnlGyzg5kYcE/lVnURbyW8DRsY0QcBeSxz05p9tI0szRxx7WkwNy8E1et9JEV7HFK8cT9SZATj6VhKR1RhbUqzgxCKWP5nIGYzyRU8pDJuaMRf3mIyfyNGqSRvfCHT4Q8qkDzUGPqTWgumsscUt3OZXzl2bkN7Csmzpgr7HP2cTS3pMgMUA5XcOtSQyRPc3RnmP7tf3YC4Dn0wK1NVAmt1eEZZ+EU/w/SsRwZkMEMSo8fLyKMMfxqXUSHGD3Zd0aHUdRWWKwhthMuPOEsyxgA9gCOaj0uGxJmu5jLJ5bmJYtpGGHXBHUVpabDbi0ZXJkvcYR1P3B61Z0W1habbLPGI48uSwyZPpWUql9maQjzdBUneOy+c75x/qwRt49Md6bqF/NDYpGQV3D50Cjd+fWoopjrGrNNDbPFawdGJHOO4p+sTO13HvQqO5bqaumru4TSijKijJdW5Ecn8PUqPc9ahvXii3W0ALM/U5PFaKTQ2pnubhGEbD5GGMGs1LZobE314rxtOcRnPBr0Iqx5lTViIGhlWJEyWXncdw/Wr3hu2NxrMklxtKwj5MnAB4rMlvwEC4BfGPcitrRUfTrF7yaJ5opOQpOamo9LFUrJ3ZdvrxvtDsLss2SCfLCkD06VnzD+0riOOxjVG/iYenrmsu3vJ9S1w/Zo0IcEFccKPpWvBaT6LcpIS7Ry9een0rj9g1q2dixKeiRUP2O3sL142Yyx/Lyu7J/GsqGwmfS5LnaIgT90nG73xXQ7Le5ZofLVIy25mwMk+9Rap+8ttqHCrwAOlSpcrsaOPMrmbpc0sduRuHmHpwK0o7jzJFhbJU8sPU1VsrWMOioS0n8RPUVacLDffuuoHzHuKcnzGEIOJFfRoZ9oGEHRaZdbVtgpzg9BUyTxzM4wC2e4pZ48hQx4HNYNWOtPQ5vUT/AKOAflA65rHum3JtXitrXzvkCKML14rGuFXoo6dxXTDY5Kl7mZI7LlMde9FWJVG4cA+xoq7GVzLt2hVYwjDnoM9a0Lt3KqqEZPYGsmGQSTCRFCH0I6Vp2bmeQ7eQDycVKZzy3NS1gECKzZ3EZNNncSTMsZwGOSx4qWTkKxOFA+tUTL/pBODgHgYrQlGnbRNuVccnt3rWmjAhRMFnP8Pes6JyIxN/GOlX7GX98bieUHaMgYNUgElkYRbVGwjj3+lWIiBpxXy/nPc8VXN4JCfKCBmP3jUttEI5R5zszddo5FFik7IS0gt4nWS/lLEfdStCObz5/KVisTD7oGQKzr+3keRZHIU9l9qtgvEwVsKgUZI75rWOhMm7DhFHZaykEZHIO5wf5+9WtNCQmWDT441XdvYlqgMtvgzRqSx+UJg7j71PYWzrburo3mOModwHHvV8xLi2ajIJsmNiSVwY24B/Gls0+ywlXuQAWwII8Nz796bbv58McUzBRGcfKME/jUkk1sJyljCXuVHJbkfkayqMqmlexTsLIzXLzM4CIxPbAPpVq3ea6u5P3atFjlnOMCpJlnWRY5o9zuMnysRgfUd6fYwMtyBysY5Cd3Ncs566HpU6PVkVijWdy8+5XLfKoBziormH7PNdXUpJuuTGh6n8KtNCs0880pMJhwVQdzj2qaBLi4hS4Kxq5OSzgdKz8zWLtscvPqcy2RREb7VcfKQV+5niux8JeBl+wxXOoyv5jfMFC1i+GrCLU/HPln95BbDeSBgN3716xdXENnatLKVSONc7c84HtXNWnyWjHcmpUk9Ecl4iijsbNlnnkuol6AKMr7cVxE8b3UIQO22T7px0FdJfanNrKiQ2xigmbhQwyAPXms63gjErRqxOOgzyKqnHS/U3pykoWaG6ffnSYGgG4bhtO0ZZvfFYV6JLe4EafL5pz8nJ/Edq2iwt52kLIz4wpIyPpVCWF3uELvtbdliR0reF7mVRLl1JYtN/dme6OBF8yqeAxqhqqS3qJdXjKYgcqmflP0NbV2qyyKpuB5YGRgHmsbz5JryJLloxDHyuxdqk/Su2L0PPkmylYWcks5aaHZETxnIOPxq5qupNM/2KBgY4x255o1K7lTEYy1xIdsSgY7/pVux0ltHuIP7ahxezAtwwYbfqpI9KptJ6k3tokM0ppDEr3IMsi/KMDt+Fasiy7RFAGTeuSxHJqxaxxmdjbBQ75AHYVJPJDpOnzNJKs1w4IIxkqfY1zVp+8dVCj1ZV0pY4xLCISXPG8f1qG4h8iKbe4HJ+6c0zwyHt4Zri8ZgjZI3Nk9aZfym6lVIELEtkduPxrmcW3c7oyUVyk2jWpXTZZZQQCDjP0rPhhlFxIDkA9Diujubd0t1iI2jb61lXUzRx+WqAscDP41mpO9ipRXIZ8UYsy/ljMhNOkZ40zN8oPNSMRDMjScknp1o1mRZdhUcen5Vck7GEZJHO32JXJY9ulY/kPJOcdAa2b6N45MshGRVefZb2zsgzK3t0rWEmkY1YpvQzJI8SFCe/NFQEyhz5vBbnNFPnZKSOPZnEy/Mwbso61tWMsnkqGJx3wOaww5jnbdjzMYzmtLSXmYfKNqDqSaqGrOGa1OgimLcZ+UDpTZColOC2fccVFHKrkQooGedwb+lSXMRgnRd24sO9dCSM9bmnBIDCSC20Vdt5VeycMvDDBx3rHS4VbcxRqZGPfpitXTbZjEEZucZ6UIm5BnGI44uhz71tWBZY/MYGNcYz3qjAIxehZG2470+8uh5pSIHAPAByKqxondGnLMjSqRudSv3iOlRw3trZxTiUtK7cKgAIz+dV0Mk9t5cZVWcc+3vUunWVuYvKkjM04bIbOM/hVbBYngEstiJxGsdwDlT6VpTQuZ4/tly8kjJyT0+lWTGIm88hSo4EQ7fU1SgM19LKY1xtHAPzVLdtxqLexqRwIZI5ACY1X7p7VfgsbgywSQRxxZYHzGJBb9DUmhWcoZQ8TZxlmboPwqfU9QMKvbIThzgsOSPoKxqVHJ8sTaFNp3bJL4fambJDXMeRluB+FYVhczS3syBSTGMZI+UGpEV7hGtreQqrkZB+99c1pSwJZfZoYv3ipgtIOMn3rKyhudEeaT3MQXrLfGK8TYSDtA7n39qS2W5lguFlkle8BPlJDzGg9zwf0q1qlzHHq5lYrtIAA27u3r2pYFfD3ME2yHo8gXOKhyN4UnLRsseHJI9Iubid3jDsnY5LnFQRXtxrU0895CVjU4C/xMAe46frUdxdte2I/wBG2QJ9244yx/3ccfnSI0sWkyNHLunPTC4yPSuWXvO52xgl0IjKTdEwxpGHYKoX+GoEhNnqL728yY8vIp4I9DVe3aWWcSyI0Rj+bbnO41DPcSXmqHA8okfdznNXTv0Jny21LElyBOAVCoQSMdBTbZZJnaaVlUe5wTSagsBUJbHBGDI7fqMU2S63zRiJS0AGNo4/HNd8I6HnVJK9i1bFZrpreTagbJVieMVSma3t9R+z22JZo1LEv93jnrUOoX7WkmY4wZcY3E/0xUmkWkMURklBluJPvMD0raMHuc05pKw6yijvr1nuWxL0UpzitrZIXMcgHlxjh5DVfS1tftsnlExbRkl0NR6hILm4dhcM+3jO0oD+dOb1siYMbpFwLa6eTJwWwqjnNRzW0t9q+FRkTO5sc5qe28hIi2D5oHBI6GtmwQSWJuH4nxjI/wAK56umrOuj7z3MnxDbyOYEgAjgjxkDqfWmW5EUiSEfIoxk1saEhnacTp5memTjFZXiJ/I3WVuuXYn5h2rl9okdqouWiLep6kJbRp4wzYGBtFZVs4vGDNkfWhVaysorUsHDck4xWtdJbW+npswrkZx71KaWocr2MG8ikhvg7EGMelPuriO4dNuAR61ae1d7IvKSSehrIhhIY5ORVxdzCpFx2Kus3W/92oGT3qCOGNYgzknjkUy7T/Sc7uBz0pbgt5BCjnvRNWREHzPUyrlRLOVTuTye1FR+b5RIAyxOSc0VjzM61GJyOt2QtZ/MiBxkn5qLOZfLyPvOOnal8Y3zLOsEY2r/AHsZrK095TOmThF9q6ISPHmtTqLZ4LdAT/rewpLy5IzLKCCeRUEc8fmB8AY/Gr1pHFcyB5DuTOcHvXRExYuimW6HzHYPUV0dnP8AY2Z5G3YGBurMiiEIIRNoPfNTeII5ba1tCMHfgkDk1aZNiKe+8/UQiAZPOeetXLceVK0crNluSVqpbW65a424bt61qW0L/ZzcSryOlaoHojUsYY1C7FJH3jnrWxbwQuTc27YdByKy7CRRFlULlhzjtV22cRylY8vuHKgdKBcxJOrFVkUkPK2D6fWui060fT4dvk7EcE+bKMnP4YqPwrp6SM8twQxDZXd2/CtHWNTt8rCRvkXgL6n1xXLUqe9yo66cWtURtezXDIscnyr1ZeM1kXtx5krOrBHU4VvX61PcRNp1od0mZ7n7sQ6gVSdVtLMFhyT35xVwUFqD5pSsS+atpGZJXZrhx8vufar+mNNNZP8AakVIQuT13Zql+6a7tZZRlMZ57GtWZXu1ljiO1X7j0rCpNNnZCk0tTDkiN2SibIo/UdW/Or9pGsdn9hQny3HQ1RudscqbA5aIgBWGA3vmpb27Yqs8RDSngxrg7ff3rCrO2x24em76lry/LhW2j3GPpg/e/wAKy7yOSO4aFWaNccM/atG8LGCIW5+Y/wCsP8R/wrPvSkUkTSOWY8FlGSo+lYwu0bSnFCXUyxWixsSZupkHYe9ULFobiZS+5ZEydycE0mquJrlBC4eJeBKcBm9iKtWax2ioVC+a+fmP+HSu2jC2rPNxFRPYimRYYZrm42SIo+VPX61V0mZJcTZ8sMeQegqvqc8ZuhbjKhuZCOec/pUDsZhiQ/u04VQNufyruUTgc0Le7tQ1gxWzIUQndIRwfpW5phTTxI8iPkdMVlxboEjHG3qqgD9TWtA8yxOLkoI8ZLZFW3oZyVyS2uJZ3+c5R+QcnK0+8RpZljAVrePklu9O0/7OLV51AZXyoUMcj3pYraSSELOQ0YORhsEflWTkky6au7Fi0jkunXylDqpwQRxite5Fva2xaKQpMRyh6fhS6DJBa2ZSJQPryf1ouEW/iLS/dXnOMc15uIqtysj1sNQW5zzX0kGXhOM8YNSzXFv9gEwUvcHqzcgHvUhskmjc5AfOFGetZ+tQf2dp65yzk9M8VgnzaHXyuL0IbOb7ZIDIMMBgAdKdqAZpFSPc5HT0H1qvpjyTMuExu69sVs48tWCqobHXOa2naMTmhJzkVY5GWArKeT27VmXsywR4H3mzjNWNQuAIvkOZAeao3aia0DsvzVxe1aloeh9XThqZT5Cl3ALntTBLJNCwIUDpinSTFgF6nFNjVthyenauxz5onlulyy0Mua38smRzhcmio9XkZgQxwM9KKy1NdjhNXYTXY82VmYH16VVjkxcBEYsMc5NUL8zy3DtM2xieBVrS1iVAMAv3JODj2FbRlZnkyNcIxiLSNtXPAFbGkTlcKEOF4Gehrnwyh8owBPdsA1p6duD5c4B6Z4rtps5pbnTC4Ii8s7ndunPSrhUyTKbklgiZCk5xWVZfu23qFb6npVi4mYo/lsM+1XcIl+wlTLSyLmNT8qqOW9q0bW5e5WQiJoQP+WbdhXPxXckca4Q7v4QozW3brvgWScET/eAPBH4VSdh76GvaM8VqRG6RFuc46/lV/wAPxXCXDlQGQjlgK5u2T7XdRyTNu2HIzxW/Pqb7mC/KdoHP0pqTYnFI221GOyj2x5Ri3zM/INUbt23wXryKHZ8RDv8AWsazjLyme7bMxbCL0IFXoiWlMMkilU6BTkU3TitQdSb0Rt3xP2qC4IM9y6gKX+YKar6reReQLEbHvmILIBytVQZxpNxAiMWJyCFOMZpNLVk4UrlVy7Kc7fr6VjOKOmg3clvpmtfstoqNNcEdAeR061sWDyfbItrSJIi/PHu61j6LY/b7me5nuvs8EeTvTBLfTPBrTsTJBbm40+KEx8jzZXKsx+n+Fc0rXsd8btlTUJppNaK3RRwR+7iiGGUY7nvRAtvYtJ5iETOd0ZbkGnRpITJJLgK/zFwcj86bPfwyC0SF180yYIyMsPUCuSSbkd8Z2Wg6GUiznluVdbrBCuD7Vg73t1Z3fzXc8nNXvE0ixzOkRxIRgjtVKxKHS5kIVztz8pzXTSSOKrtuO8pSqSviGJjwSOpqsLn9/I7nJThQe9VIJpGjVpSmwfKCTz9Kics8uJHxHnIXvXfThdHnTnbQnkK7Gn2/vH5ORUlgIpiPMlAUfwqfmqOOHz5Ve4jKADhsdBWzZPHcyx253+QOcxjc2a1k+VGNuZjIJHjlXZaxSKzlRHIm5vrmtCbT/wC0bpba5mjhCjcwgGwY78CmXLq+oG2kAggQcc4ZvcirMDyadYyM9zAbU/cWNwTn6VzSqHQqVttStNawW03/ABLmAVRhie5rRtRugDAEvnqopGhxp8c6y3K3Ex+VDEAD/WpprOaxtY3MU5vPVYyetQ6isXytvYsRtHD+6lMLzMCQAvzLSW91+6kiCyN67TjHtUFteJZ4dwPPbkrn5ifp1rQitmdxcyMq7xnk4Iriqxu7npYaVtGZxlgsphNNkHH5VhazdnVrsKjLFagnk9D71Y1tWFxI8ZDL6np0rLgZSMSny0J5J6UqcElcqpUblZHQadFCw22+BgEHjmq2qzNaRyKh/eAcN361f0wW32dnjQqoBwTVPV7iCXbGrgk8YzXNKTlodVOMYanORToCPNBeQnPPNSahKRFnb26CotVLwyKkSEEnqR2qtPchrfYzAuOoz0rNLU6JzXIZvmOJMlcA1Z83bH6k9D3qpvO4k8Acc1WmmB3DNd8IXR4dWquYraorMecnJ70VWlk+VgOOe9FV7Mz9qcfr9moYyhgAM81iWt1tyFG5ieD7VduNSt9S01J0fER/g9/SqVrtMyuRhTwAOlYRktzneprW6nCl/mZula1urAKJXP0otwkqLtXBAH0qWVDbESMQcnovOK6adQwdPU2LRv3OFPY8mp4B2PJ9PWs+xLiPan3m5JPQVoqBAuS/7xvvemPat1MXJYsWyq0nmu20L2960FE7zCYNhMcg96yhIGlVY23A8n0q7N58vy2zBdvVm4xVpjcTR0O4SMuxGH5GSM4q2+6a4ARdq8Hce9Zmnr5cysjZwPnJ7mtZWQyvMxbcANqgVanYSiy4gjERWbLyr0Ze1WILYpcbZGwrDLP6VVs3Ej5wFycFvWrr3C4wp35G07aUqhcaeupoW1zHM8qxMCsS4xis7TGkEs+SoViQQBzii/RbRIXsmUyNyyZ6/WprSIQO1xIjGV1J2DoDXPOR2U4pPQt3UDpZILUgKxOVzipJopZLHEqvDDGvAVvvflWLfLcFFuJpmQBsmNOmPatXUdUWexi+xh22qBmQYC/lnmueTZ2KzKsl3cyac6geWi9FJBJFUYEUpBcr1U5OfWpVi2E+a5dnGc1XNxCtu1q3M5fgetEQlZdSO9v1v9VM0pCnGOhwfbFM1A/ZRHDaA75vvj0FVJC2DJGzySR8n/ZpIJCyPO5Z3bgZ6jmuiMddDmlJWbF8gRLl2JCnOKXDPKsu0KvZcg02V3yRJk7jwnf60y1kJbYwxzgHtXZHRanBJ3NK7mM0KKg2MDgmt6ytXaBbqyUO0Y/ebRt2/gcfpWfpNslxOsEhXfjOf4auyXlzZzSLDIyIPlIT7rcVFSV1ZFQj1Ze0VIru8uJ7gKzKveqmm266pePMbd5LSEn5VYLn86o/amaN4ov3ckv8Q61taZpx0nTJJZbhssCxXseK55R7nQp20LUEymQvgpGvAic7ig9jWjfXo+ysGlGSPlauQtrtWvD8n7s91q1rEkVxcRpF5sajHDYGT+BqXDuNSd9COxt3TUBczvlCfvNyK3bybbH+5blh68VRlR7WCJLhFkiYcbOfzzikuoYILLejSEv/AAY/+vXPU3Oyne1ylIrT3IhZ1bPWoNQ0pjKqJ0HUZGKuabHEQ0jRyo3rgc/rSvMpZx83XpWcq3LojWnR5tWMhleKzaJBng/hWXb4F2Wc7nz6dK12aO2scbwzN6ViO4S4Z1YDPrURSlqVJtKxB4hdkYKgxIfU9qwJCINpbljnNbGrMkhDb/mHrWHMRIMDPHXPQ1cKXUipXSjYryyFySOBVSU4JA6nvVxEA3FifQCqs+1XO4Yz6dBXXeyseZJ3dzPuB8pzng4orkfiF4lXTYmsrN83sow57xKe/wBaKydeMXZiPMNMvWtJRkkxH7y5ruNKt5LtFkjK+VjcDnrXnddD4X1uSykW1mf/AEWQ7c/3D6158ZWEelaYWPy9hV2RsvyQVB9Kp2yx2/l/vCcgEe49amvnDvtTgd8Vqp2ZtGN0W7K7DB0H3u3NXk3NEA35mueRWLA7iuPStKO8Ozbjp1rrjVRi6bNq2aOIDYOO5q8zsfkUYU8k1nQSB4QzhUA9B1qysjMytg7TwPWtYzuZuNkTi5w6LGhwOvOK01dndVJ2sew5rJO5HyeQoywFaVm6SsssY+YDvWnMOKubViY47eZBlXxnDdqi0LO55ZXAbB+WqwdpHK7gfUnt7Vfs4UVtwHy4wx/wqXM1Ubl2G03Rm4hk3OW5THvWpq0kdr9nW0G+ZwBJntUA2TWkaWQEXl8sx+8TVaYu0E8iK7MeN4P3awnPU6qcFYdqsRVEdzheSwznP0FV7WNTE8j8RkfKgOCadAz+QgcrIezntViOAxEGSNirjhu9RzI2UWuhC0ZsdhiHzSLkqfmwPrXPz+Wt7JNgg5JVjWpLc3MVy4ZlSEcLvB3H8jWdeRq1sm5ZNyuT83etoamU5q1mRR7ts0yN5e/r3BqzA6Qw+coA9Sec1FdbGtVhUYK9h0piRN5WFA2e9dNPzOKT0HOI57kSnOaJIhDgvnGcrj1qmRO82Nuy3B5fufarscjXdxHCciJD1Xr+Oa3exhc3tNdo4keVVaRlxw2Diqf21p7loHRljU8d6u3skcKL5USg4wGxkmsqPzopDNKWCE5PPJrBqzNlO8Ujo7G0bzkuD5YReACeTVHxDfC5nEKyts67KdZq1yI3tgGjPUydqp6ygeUyRKpZQTuTpWF/e1OjlXLdDLeRo0IglCMvK5XNbttI1xAhvHG/PUR9K5rTUSQea8rF8/dQ8fqK25JxbQb2LKx4AzWlSxjBvmI77VJpb1Yo1Z4k4wP/ANVagUyKhHyjrzzWZZyqqq8bEux5IrVhJ3qzMuD2auGpJXPSpJ7kkr7wojB3enQUy6U7QsqqO3Hap76cRhWRUY4429KoNM8vzSAhs5A7VytNs7FNWsQz6ciR+aXJQA4GKz/Lt0hlluD0Hyp+PrSz3kpUqSNi88VhX108kgULxnvXTTgziqzIJ0aSRpNp8vOBzVViu4qvOfwrSuCIbXMrD1CisV5vnLYAU/pW8dDkm9LizYiUlyA3UD1rkvG/iOPQrAuNr3s4xDF1GMY3H6Vf8Ta3BotjJeXbjIBESZy0jdgB/OvB9a1O51bUZby8ffK+PYAAAAD8AKitU5FZbmNyveXUt5dS3Fy7STSMWdieSTRUNFcDbYgooopAdr4I1ZJp0sNRmYZ4hY9z/dJ/l2rublPsgPmckdDXiQyP516BoPiM6pbR2l5IBcxKApY/6wD+vtTTNqVSzsdXGy/ZTzlj371ZimC24Vh6c45rKsmKu2clvQ1qXcZiMOHCs3JI4raDsazi3sbsEiQFWK7uOOc4q7YkS3GcZDdR6Vi2rMXEYOS3Ga3bYeQ6qDh+hPc1sqiSOfkbdjQaOK1jYglmYY4Gap2Nx5UhQAkHqxGP0pby7+xxlTy5GRVW2fMLO/LseM0e1bOhUlE2ohtyyPgFueM5rY3xQWkYUK4B5w/Nc7C5wquSuO4PSr8c6W9nLIcMU7nqTT5mVyGisskMwcvnzeAvTFWrhpECxwSEbz+84zn2xWXpvm3Oye54fqsZ5AHrircc5n83C7XQ5Dev0qZu5pTjZm3ZLpgMf9pySpAn3VRT8ze5HTtVW7uLiS+AlKiJQQijHA7VlvceSElncs7nGxjkVavJiJYDsHmAd+mKzhG71NqjcXuL5azfJMwUZygI61HdRO90sCmNAP4WYc1FbmT7a9zK2+NcAK3Kj6DtU14IJna6yRKOzdq7IS5TinDnMlSguiqKWiAwwqOcMnyxyna33VxVi03fMFT5z1B71TunkSU74SoHf/Ct6c7mE6bQs0im1KMcSKcdetXbbdHbxohCM3UHr+dYcUgN4iv82TwDzW0xgjmjc3KBx/BKC2a1c9DncGdLbQqLMiB8uo+Z25/AZrD1Ah2VIGLOSM+/rxVpLySNM8eWw6Dp+VQSFNwmttucgZxXM5M6Yx0Rv6Zbb9OLQGNJF5KtJjNc7reordTiJTskX72BWjd3sdtpbOyEzn8vxrAithOPtcg5bnjrWUItyuzplUioWRrW4jKRpGv7sj5s8frSSBILpTbDn0Lbv51X+0okCRo5JJxtz81X7CC3hPmySl5SOFY5reo7HLF+9c2bRnmjV5o0OOxwn8qW4dkJZsImOAuDSRXIdVLoAfQVU1W5/ckB9ox3zXnyTcj0I1EkNtZA97uV8qeuTTdRu3LlAvyZ6isbTwzNIwlZ29QTgVZmcxW5EsuGPTBrVUjL2r3IL642Q7Y13DvWS86lgznp2pkl25fy1JY9smo5rY7WZmO8joK6YxstTlnO4lyyznLHd7dKxtZ1O10yxe5uJBHDGDkn+I9l+pp73AiSWSaUrFECzsTwoHUn/PpXiXjjxO+v32y3LJYREiMMeX/2m/Lp2qKs1Tjcz5mzO8T65Prmom4k3LEuRFGT9xc5/P3rHNBorzZScndgFFFFSAUUUUAFOikaGVZIm2uvIIoooA9I8KakupWpL8TocMuOD710FzLKzLvblcDPtRRVI6KbvuaenTFbxS3YZzW/blCGOSdx60UUmzaO5BqOcxL97J6URXMUbSBwWkRePaiimnobLYuWcrOc3LF1POzsParcUu+78nJ2HjbRRWjbsEYps0YjiOVYh/qxkg06CSNUjnkLOWztPofSiipvdnQklsV7RsaiVLnD5Iq7C0QkJkZsk4GB2oorU5pbjrlyHxE5KY4U1X3+Si/89S2QvY0UVpAhbiW939nkKvGCrjGKy76+ea52SnMan5V9KKKsOhHbbWvNyfKxOTWxeyiMoWHPY0UVvFnHUWpNEy3EYmlYyMo4z2FMlkDRNdJyg4IPbHFFFKQ47FAzwz3SyBScdM1anujINjcZ44ooqo7im9CK1ytwFjYhm6GtqW4nhQfaMOMUUVVXYyp6yLFnffu/MjQbR2qtqF/HLkmP56KK418R2soR3ew53Eq1OIVlJUnJOaKK2Od7mHJ88jkE1LCXMJTAOe1FFdMDlZ4v8TvFv264k0nTmYWcT/vZMFWkcZGP90Z6V56aKK8nESbm7msdhKKKKwGFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic image of diffusely-stained, long-segment Barrett's esophagus with an area of heterogenous staining (pink or unstained mucosa) corresponding to high grade dysplasia, which was confirmed by biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcia I Canto, MD, MHS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30656=[""].join("\n");
var outline_f29_60_30656=null;
var title_f29_60_30657="Basic management LUTS men";
var content_f29_60_30657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Basic management of LUTS in men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 598px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DRE: digital rectal examination.",
"     <br>",
"      * When life expectancy is &gt;10 years and if the diagnosis of prostate cancer can modify the management.",
"      <br>",
"       &bull; When significant nocturia is a predominant symptom.",
"       <br>",
"        &Delta; Assess and start treatment before referral.",
"        <br>",
"         &loz; In practice, advise patients with symptoms to aim for a urine output of about 1 liter/24 hours.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Abrams, P, Chapple, C, Khoury, S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181:1779. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30657=[""].join("\n");
var outline_f29_60_30657=null;
var title_f29_60_30658="Lepromatous leprosy";
var content_f29_60_30658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lepromatous leprosy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized skin disease with prominent nodules on the face and earlobes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from McDougall, AC, Yuasa, Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto, RS, Abalos, RM, Cellopna, RV, Fajardo, TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30658=[""].join("\n");
var outline_f29_60_30658=null;
var title_f29_60_30659="Atheroma on CT";
var content_f29_60_30659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/SURG/68662/Atherorma_CT_movie_PR.mp4?title=Atheroma+on+CT\" style=\"width:384px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atheroma on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive, partly calcified plaque in the descending thoracic and abdominal aorta visualized by axial CT imaging.",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Pierre Maldjian.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30659=[""].join("\n");
var outline_f29_60_30659=null;
var title_f29_60_30660="Metipranolol: Drug information";
var content_f29_60_30660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metipranolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/17/20756?source=see_link\">",
"    see \"Metipranolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OptiPranolol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      OptiPranolol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glaucoma: Ophthalmic: Instill 1 drop in the affected eye(s) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.3% (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OptiPranolol&reg;: 0.3% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11563684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not allow the dispenser tip to touch the eye. Remove contact lenses prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Metipranolol may be confused with metaproterenol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betanol [Monaco] may be confused with Beta-Val brand name for betamethasone [U.S.]; Betimol brand name for timolol [U.S.]; Patanol brand name for olopatadine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, atrial fibrillation, bradycardia, hypertension, MI, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, headache, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, blepharitis, blurred vision, browache, conjunctivitis, discomfort, edema, eyelid dermatitis, photophobia, tearing, uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metipranolol or any component of the formulation; bronchial asthma, severe COPD, sinus bradycardia, second- and third-degree AV block, cardiac failure, cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD): Use with caution in patients with PVD (including Raynaud's).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9951561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9951562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metipranolol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (5 mL): $29.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optipranolol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3% (5 mL): $25.38",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Beta Ophtiole (AT, BE, NL, PH, PT, TW);",
"     </li>",
"     <li>",
"      Betamann (LU, PL);",
"     </li>",
"     <li>",
"      Betanol (FR);",
"     </li>",
"     <li>",
"      Glauline (GB);",
"     </li>",
"     <li>",
"      Minims Metipranolol (GB);",
"     </li>",
"     <li>",
"      Normoglaucon (DE);",
"     </li>",
"     <li>",
"      Trimepranol (CZ);",
"     </li>",
"     <li>",
"      Turoptin (CH, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beta-adrenoceptor-blocking agent; lacks intrinsic sympathomimetic activity and membrane-stabilizing effects and possesses only slight local anesthetic activity; mechanism of action of metipranolol in reducing intraocular pressure appears to be via reduced production of aqueous humor. This effect may be related to a reduction in blood flow to the iris root-ciliary body. It remains unclear if the reduction in intraocular pressure observed with beta-blockers is actually secondary to beta-adrenoceptor blockade.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &le;30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Maximum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Intraocular pressure reduction: Up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid and complete to deacetyl metipranolol, an active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30660/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30660/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9641 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30660=[""].join("\n");
var outline_f29_60_30660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195525\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195526\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195545\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195527\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195528\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195512\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195498\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11563684\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195513\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195543\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195517\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195502\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299704\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195507\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195508\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9951561\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9951562\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524687\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195519\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195501\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195516\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/17/20756?source=related_link\">",
"      Metipranolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_60_30661="Hydroxyethyl starch (tetrastarch) 130/0.4: Drug information";
var content_f29_60_30661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxyethyl starch (tetrastarch) 130/0.4: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/46/19171?source=see_link\">",
"    see \"Hydroxyethyl starch (tetrastarch) 130/0.4: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/21/11605?source=see_link\">",
"    see \"Hydroxyethyl starch (tetrastarch) 130/0.4: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10074407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Voluven&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10074408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Volulyte&reg;;",
"     </li>",
"     <li>",
"      Voluven&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10074412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Plasma Volume Expander, Colloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10074444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Plasma volume expansion:",
"     </b>",
"     I.V. infusion: Administer up to 50 mL/kg/day (or up to 3500 mL per day in a 70 kg patient); may administer repetitively over several days.",
"     <b>",
"      Note:",
"     </b>",
"     With severe dehydration, administer crystalloid first. Daily dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10074443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/21/11605?source=see_link\">",
"      see \"Hydroxyethyl starch (tetrastarch) 130/0.4: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Plasma volume expansion:",
"     </b>",
"     I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     With severe dehydration, administer crystalloid first. Daily dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children &lt;2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer labeling: Average dose: 7-25 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Unlabeled dosing: 10 mL/kg/dose (range: 7-50 mL/kg/dose) individualized to patient colloid needs based on intraoperative hemodynamic and hydration status (Chong Sung, 2006; Hanart, 2009; Lochb&uuml;hler, 2003; Osthaus, 2008; Sumpelman, 2008; Witt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2-12 years (unlabeled dosing): 10 mL/kg/dose (maximum dose: 50 mL/kg/day) individualized to patient colloid needs based on intraoperative hemodynamic and hydration status (Chong Sung, 2006; Hanart, 2009; Osthaus, 2008; Sumpelman, 2008, Witt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;12 years: Administer up to 50 mL/kg/day (or up to 3500 mL per day in a 70 kg patient); may administer repetitively over several days.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10074445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10074446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; closely monitor volume status, infusion rate, and urine output. Use is contraindicated in oliguric/anuric renal failure unrelated to hypovolemia and patients receiving hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10074447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10074457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voluven&reg;: 6% (500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13940442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in isotonic electrolyte solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Volulyte&reg;: 6% (250 mL, 500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10074410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10074450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. only; may be administered via infusion pump or pressure infusion. Infuse the initial 10-20 mL slowly while observing for possible anaphylactoid reaction; have epinephrine and resuscitative equipment available. If administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Do not use if crystalline precipitate forms or is turbid deep brown. Change I.V. tubing at least every 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10074415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood volume expander used in treatment and prevention of hypovolemia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10074424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (dose dependent; may be delayed), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Amylase levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia, aPTT increased, coagulation factors prolonged, hemorrhage from wound site, PT prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute kidney injury, anaphylactic reaction, anaphylactoid reaction, bradycardia, bronchospasm, circulatory collapse, flu-like syndrome, hypersensitivity reaction, hypotension, pulmonary edema (noncardiac), shock, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10074418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydroxyethyl starch or any component of the formulation; renal failure with oliguria or anuria (not related to hypovolemia); dialysis; any fluid overload condition (eg, pulmonary edema, congestive heart failure); severe hypernatremia; severe hyperchloremia; patients with intracranial bleeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10074419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Anaphylactoid reactions have been reported with solutions containing hydroxyethyl starch; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, elderly patients, or those with heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemodilution: Large volumes may cause a reduction in hematocrit, coagulation factors and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders (eg, von Willebrand&rsquo;s disease): Use caution in severe bleeding disorders; may increase the risk of more bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Critically-ill patients: The use of hydroxyethyl starches (HES), including tetrastarch, is associated with an increased risk of acute kidney injury (Reinhart, 2012). Additionally, in a meta-analysis of mixed critically-ill patient populations, the use of HES did not demonstrate statistically significant differences in mortality compared to crystalloid therapy (Perel, 2011). In review of clinical trials including patients with severe sepsis or septic shock, a meta-analysis of HES trials demonstrated a trend toward increased mortality (Zarychanski, 2009). In patients with severe sepsis, a trend towards higher mortality at 90 days was observed in one clinical trial comparing HES 200/0.5 (pentastarch) to Ringer&rsquo;s lactate (Brunkhorst, 2008). In addition, the use of HES 130/0.42 (Tetraspan&reg;; similar to tetrastarch) has been shown to increase mortality in patients with severe sepsis as compared to Ringer&rsquo;s acetate (Perner, 2012).  The Society of Critical Care Medicine has recommended either crystalloid or iso-oncotic colloid (natural or artificial) therapy for fluid resuscitation in patients with septic shock (Dellinger, 2008). Hyperoncotic solutions should not be used for fluid resuscitation (Reinhart, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; may result in further reduction of coagulation factors, increasing the risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Use is contraindicated with oliguria or anuria unrelated to hypovolemia or patients receiving hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not a substitute for red blood cells or coagulation factors. Severely dehydrated patients should be infused with a sufficient volume of crystalloid solution prior to administering tetrastarch.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10140508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10074416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10074417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17917133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tetrastarch is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetrastarch to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Voluven Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-0.9% (500 mL): $61.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10074453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, capillary refill time, CVP, RAP, MAP; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin, coagulation parameters, renal function, urine output, acid-base balance",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tetrahes (ID, KP);",
"     </li>",
"     <li>",
"      Tetraspan (DK, EE, HK, PH, TW);",
"     </li>",
"     <li>",
"      Volulyte (CZ, DK);",
"     </li>",
"     <li>",
"      Voluven (AR, AU, CH, CL, CN, EE, FI, FR, GR, HK, HN, ID, IL, KP, MY, NO, NZ, PH, SE, SG, TH, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10074432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces plasma volume expansion by virtue of its highly colloidal starch structure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10074434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &ge;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5.9 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Molecules &gt;50,000 daltons are metabolized by plasma &alpha;-amylase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (smaller hydroxyethyl starch molecules [&lt;50,000 daltons] unchanged, metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      ,  2008, 358(2):125-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/18184958/pubmed\" id=\"18184958\" target=\"_blank\">",
"        18184958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chong Sung K, Kum Suk P, Mi Ja Y, et al, \"Effects of Intravascular Volume Therapy Using Hydroxyethyl Starch (130/0.4) on Post-Operative Bleeding and Transfusion Requirements in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2006, 50(1):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/16451158/pubmed\" id=\"16451158\" target=\"_blank\">",
"        16451158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327; published erratum appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanart C, Khalife M, De Vill&eacute; A, et al, \"Perioperative Volume Replacement in Children Undergoing Cardiac Surgery: Albumin Versus Hydroxyethyl Starch 130/0.4,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):696-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/19114887/pubmed\" id=\"19114887\" target=\"_blank\">",
"        19114887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lochbuhler H, Galli C, and Hagemann H, \"Hydroxylethyl Starch HES 130/0.4 in Paediatric Surgery: Results on an Explorative, Controlled, Multicenter Safety Study,\"",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2003, 7(2 Suppl):107.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osthaus WA, Witt L, Johanning K, et al, \"Equal Effects of Gelatin and Hydroxyethyl Starch (6% HES 130/0.42) on Modified Thrombelastography in Children,\"",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2009, 53(3):305-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/19173690/pubmed\" id=\"19173690\" target=\"_blank\">",
"        19173690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2012, 6:CD000567.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/22696320/pubmed\" id=\"22696320\" target=\"_blank\">",
"        22696320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(2):124-34; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):481.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/22738085/pubmed\" id=\"22738085\" target=\"_blank\">",
"        22738085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2012, 38(3):368-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/22323076/pubmed\" id=\"22323076\" target=\"_blank\">",
"        22323076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      S&uuml;mpelmann R, Kretz FJ, G&auml;bler R, et al, &ldquo;Hydroxyethyl Starch 130/0.42/6:1 for Perioperative Plasma Volume Replacement in Children: Preliminary Results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS),&rdquo;",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2008, 18(10):929-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/18647272/pubmed\" id=\"18647272\" target=\"_blank\">",
"        18647272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Witt L, Osthaus WA, J&uuml;ttner B, et al, \"Alteration of Anion Gap and Strong Ion Difference Caused by Hydroxyethyl Starch 6% (130/0.42) and Gelatin 4% in Children,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2008, 18(10):934-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/18811828/pubmed\" id=\"18811828\" target=\"_blank\">",
"        18811828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo;",
"      <b>",
"       ATTENTION:",
"      </b>",
"      The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release.",
"      <i>",
"       Open Med",
"      </i>",
"      , 2009, 3(4):e196-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?29/60/30661/abstract-text/21688756/pubmed\" id=\"21688756\" target=\"_blank\">",
"        21688756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8728 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30661=[""].join("\n");
var outline_f29_60_30661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074408\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074412\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074444\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074443\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074445\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074446\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074447\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074457\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940442\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074410\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074450\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074415\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074424\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074418\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074419\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300129\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10140508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074416\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079782\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074417\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917133\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322845\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074453\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962021\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074432\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10074434\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/46/19171?source=related_link\">",
"      Hydroxyethyl starch (tetrastarch) 130/0.4: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/21/11605?source=related_link\">",
"      Hydroxyethyl starch (tetrastarch) 130/0.4: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_60_30662="Reproductive issues in women with uterine leiomyomas (fibroids)";
var content_f29_60_30662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reproductive issues in women with uterine leiomyomas (fibroids)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30662/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/60/30662/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with uterine leiomyomas depends upon several factors, including the patient's age and symptoms, her obstetrical history and future childbearing plans, and the size and location of the leiomyomas. A general approach to counseling women with leiomyomas about reproductive issues will be reviewed here. Effects of fibroids during pregnancy and other fibroid-related issues are discussed in detail separately (see individual topic reviews). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC LEIOMYOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A uterine leiomyoma in an asymptomatic woman is usually an incidental finding. Although some of these tumors will naturally regress, others will continue to grow and new leiomyomas may develop. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H22#H22\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of low dose estrogen-progestin contraceptives does not cause leiomyomas to grow; therefore, administration of these drugs is not contraindicated in women with leiomyomas who wish to use this method of contraception. One possible exception is girls with exposure to estrogen-progestive contraceptives between the ages of 13 and 16 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/1\">",
"     1",
"    </a>",
"    ]. In adolescents, the advantages of estrogen-progestin contraceptives need to be weighed against this potential risk. On the other hand, use of depot-medroxyprogesterone acetate protects against development of leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H5291214#H5291214\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Hormonal contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRECONCEPTIONAL PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that women with leiomyomas not postpone pregnancy for a prolonged period of time, if possible. Our rationale is that fertility naturally declines with age, especially after age 35, and leiomyomas may impair fertility and adversely affect pregnancy outcome (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Infertility and miscarriage'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There are no well-designed studies that provide high quality data on whether leiomyomas adversely affect pregnancy outcome. Instead, the available information consists largely of observational case series and case reports that are limited by different patient populations; different criteria regarding the size, location, and number of leiomyomas; small numbers of adverse events; ascertainment bias in selecting study participants; and inadequate adjustment of confounders.",
"   </p>",
"   <p>",
"    In the absence of high quality data, we suggest not performing prophylactic myomectomy to prevent pregnancy complications. Myomectomy can be considered in selected patients with a history of obstetrical complications that appear related to the presence of leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INFERTILITY AND MISCARRIAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas are estimated to account for 1 to 2 percent of infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/2\">",
"     2",
"    </a>",
"    ]. Fibroids, particularly those that impinge upon the endometrium, may affect fertility by interfering with implantation over the myoma site, rapidly distending the uterus in early pregnancy, or impairing uterine contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of a fibroid, and not its size, is the key factor regarding fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/4\">",
"     4",
"    </a>",
"    ]. Leiomyomas that distort the uterine cavity (submucosal or intramural with an intracavitary component) result in difficulty conceiving a pregnancy and an increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast, subserosal fibroids do not impact fertility. The role of intramural fibroids in infertility is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a meta-analysis of 23 studies that compared infertile women with and without leiomyomas (including one randomized trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/4\">",
"     4",
"    </a>",
"    ]. Women with fibroids that were submucosal or intramural with an intracavitary component were less likely to become pregnant (RR 0.36, 95% CI 0.18&ndash;0.74) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.4&ndash;2.1). Consistent with these findings, women with cavity-distorting fibroids who did versus did not undergo myomectomy had a significant increase in conception rate (RR 2.03, 95% CI 1.08&ndash;3.83). Interestingly, there was no significant decrease in the risk of miscarriage in women who did versus did not undergo myomectomy (38.5 versus 50 percent; RR 0.77, 95% CI 0.36&ndash;1.66); however, this result was based on a single study of 52 women and lacks adequate statistical power [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data regarding intramural fibroids are less clear. Overall, studies of women with fibroids that did not distort the uterine cavity were less likely to become pregnant (RR 0.81, 95% CI 0.70&ndash;0.94) and more likely to have a spontaneous abortion (RR 1.7, 95% CI 1.2&ndash;2.5). However, most of these studies may have included women with fibroids causing intracavitary distortion since fibroid location was determined by imaging methods (HSG, ultrasound) less reliable than hysteroscopic documentation, thus biasing the results.",
"   </p>",
"   <p>",
"    Clinical questions remain about the effects of intramural fibroid positions other than extension into the uterine cavity. As an example, it is possible that a fibroid near a fallopian tube ostium or near the cervix may impede fertilization. The two small series that evaluated whether treatment of occluding fibroids improves fertility reported conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Couples should complete a full infertility evaluation before addressing the role of leiomyomas in their infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preparing for in vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of leiomyomas on IVF is dependent upon their location: submucosal myomas decrease the chance of success, whereas subserosal myomas do not appear to have any effect. Observational data suggest that intramural myomas may also have a negative impact on IVF outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link&amp;anchor=H4#H4\">",
"     \"In vitro fertilization\", section on 'Pre-cycle factors associated with success'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OPTIONS FOR TREATMENT OF LEIOMYOMAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medical therapies for uterine leiomyomas preclude conception, cause adverse effects when employed long-term, and result in rapid symptom rebound when discontinued. Therefore, medical treatment of leiomyomas in infertile patients attempting to become pregnant is usually unsuccessful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Myomectomy versus embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer myomectomy over uterine fibroid embolization (UFE) for treatment of most women with uterine leiomyomas who wish to conceive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/9\">",
"     9",
"    </a>",
"    ]. However, we suggest UFE in women at high surgical risk, such as those with previous multiple laparotomies or diffuse uterine leiomyomas where myomectomy might not be technically feasible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22473?source=see_link\">",
"     \"Uterine leiomyoma (fibroid) embolization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally avoid UFE in women who wish to conceive because the safety of the procedure with respect to subsequent pregnancy outcome has not been established; fewer than 150 pregnancies following UFE have been reported. Cohort studies suggested that the miscarriage rate after UFE was higher than after myomectomy (17 to 30 versus 15 percent); the rate of preterm delivery was also higher following UFE than myomectomy (16 to 22 versus 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In two studies, the rate of postpartum hemorrhage was high (18 versus 1 to 5 percent in the general obstetrical population), which could have been related to abnormal placentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Interpretation of these data is limited because all of the studies involved a small number of patients and had no age-matched controls. Women in the UFE group were of older age, which could at least partially account for these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Route of myomectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hysteroscopic myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic myomectomy is the procedure of choice for submucosal myomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32601?source=see_link\">",
"     \"Hysteroscopic myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Abdominal myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal myomectomy is the treatment of choice when there are multiple myomas, more than three leiomyomas of over 5 cm, or the uterus is significantly enlarged (&gt;18 gestational weeks' size). The operative time, blood loss, and hospital stay are comparable to that with abdominal hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The risk of unplanned hysterectomy at the time of myomectomy is less than 1 percent for experienced surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12346?source=see_link\">",
"     \"Abdominal myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After abdominal myomectomy, the risk of uterine rupture prior to labor is very low (about 0.002 percent) compared to after classical cesarean delivery (about 3.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/18\">",
"     18",
"    </a>",
"    ]), although these data are based upon small series without complete pregnancy follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The common clinical practice of counseling women who have had a myomectomy with a transmural uterine incision to undergo an elective cesarean delivery clearly biases and under-reports the risk of rupture at term.",
"   </p>",
"   <p>",
"    Women who undergo myomectomy with significant uterine disruption should wait several months before attempting to conceive; recommendations for delay range from three to six months. In addition, if a woman is having difficulty conceiving following a myomectomy, early assessment of the uterine cavity and fallopian tubes with a hysterosalpingogram is advisable to make sure there is no obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/21\">",
"     21",
"    </a>",
"    ]. Myomectomy, particularly near the oviduct, can cause adhesions that may impair fertility.",
"   </p>",
"   <p>",
"    Pregnancy rates reported from 2 to 14 years after abdominal myomectomy range from 42 to 87 percent, depending on age and history of infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laparoscopic myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With advances in laparoscopic suturing technique and instrumentation, most myomectomies can be performed laparoscopically. The results are comparable to those of myomectomy by laparotomy. Moreover, the laparoscopic approach is associated with faster recovery, and less adhesion formation. However, without proper suturing of the uterine defect, there is a risk of uterine rupture during the subsequent pregnancy or in labor. Multilayered closure and meticulous hemostasis are mandatory. Only surgeons who are familiar with laparoscopic suturing should perform laparoscopic myomectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8970?source=see_link&amp;anchor=H7666064#H7666064\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic myomectomy is an option in women with a uterus of &lt;18 weeks' size, with &le;3 intramural or subserous leiomyomas of &le;5 cm in diameter. Factors reported to lead to an increased risk of conversion to an open procedure include size &ge;5.0 cm, intramural or anterior location, and preoperative use of a GnRH-agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/26\">",
"     26",
"    </a>",
"    ]. The magnitude of increased risk depends on the surgeon's experience and laparoscopic skills.",
"   </p>",
"   <p>",
"    Whether reapproximation of the myometrium via laparoscopic suturing gives the uterine wall the same strength as multilayer closure at laparotomy is an area of controversy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/21,26,27\">",
"     21,26,27",
"    </a>",
"    ]. Ten cases of uterine rupture in women who underwent laparoscopic myomectomy have been reported, one was at 17 weeks of gestation and the remainders were at 27 to 35.5 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/28\">",
"     28",
"    </a>",
"    ]. On the other hand, one of the largest series of pregnancies after laparoscopic myomectomy reported no uterine ruptures in 106 deliveries; 27 of the deliveries were vaginal. Only 10 uterine cavities in this series had been entered at myomectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/29\">",
"     29",
"    </a>",
"    ]. We believe the differences are due to different surgical technique and skill of the laparoscopist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Miscellaneous techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoma coagulation or myolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/30\">",
"     30",
"    </a>",
"    ] is associated with adhesion formation and may increase the risk of uterine rupture in pregnancy. For these reasons, most gynecologists no longer perform this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8970?source=see_link&amp;anchor=H432924#H432924\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Myolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy and safety of other procedures, especially in young women who wish to conceive, have not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30662/abstract/32\">",
"     32",
"    </a>",
"    ]. These techniques include occlusion of uterine vessels either via laparoscopy or a vaginally-placed clamp, high intensity focused ultrasound (HIFU), cryomyolysis, and magnetic resonance imaging-directed cryotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest women with asymptomatic leiomyomas not postpone pregnancy, if possible, since leiomyomas, combined with advanced maternal age, may impair fertility and adversely impact pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Asymptomatic leiomyomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women planning pregnancy, we suggest not performing prophylactic myomectomy to prevent pregnancy complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infertility and miscarriage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationship between leiomyomas and infertility is controversial. Couples should complete a full infertility evaluation before addressing the role of leiomyomas in their infertility. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infertility and miscarriage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with asymptomatic leiomyomas who are infertile or have a history of recurrent pregnancy loss:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those with a myoma that is submucosal or has an intracavitary component, we suggest myomectomy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For women with a myoma that is subserosal, we suggest against myomectomy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For women with intramural fibroids that do not distort the uterine cavity, other sources of infertility should be addressed prior to a myomectomy. The decision to perform a myomectomy should be made based on patient preference and clinical factors (eg, obstructing of a fallopian tube or the cervical canal or failure of other infertility treatments). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Infertility and miscarriage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest myomectomy for women planning to undergo in vitro fertilization who have a submucosal fibroid or an intramural fibroid that deforms the uterine cavity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preparing for in vitro fertilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical myomectomy over medical therapy or embolization for women planning future pregnancies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Options for treatment of leiomyomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/1\">",
"      Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/3\">",
"      Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/4\">",
"      Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/5\">",
"      Orisaka M, Kurokawa T, Shukunami K, et al. A comparison of uterine peristalsis in women with normal uteri and uterine leiomyoma by cine magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 2007; 135:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/6\">",
"      Casini ML, Rossi F, Agostini R, Unfer V. Effects of the position of fibroids on fertility. Gynecol Endocrinol 2006; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/7\">",
"      Guillaume J, Benjamin F, Jean-Gilles M, et al. Myomectomy and tuboplasty performed at the same time in cases of distal tubal obstruction with associated fibroids. J Reprod Med 2000; 45:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/8\">",
"      Gardner RL, Shaw RW. Cornual fibroids: a conservative approach to restoring tubal patency using a gonadotropin-releasing hormone agonist (goserelin) with successful pregnancy. Fertil Steril 1989; 52:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/9\">",
"      Tulandi T. Treatment of uterine fibroids--is surgery obsolete? N Engl J Med 2007; 356:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/10\">",
"      Goldberg J, Pereira L. Pregnancy outcomes following treatment for fibroids: uterine fibroid embolization versus laparoscopic myomectomy. Curr Opin Obstet Gynecol 2006; 18:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/11\">",
"      Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for leiomyomata: a series of 56 completed pregnancies. Am J Obstet Gynecol 2006; 195:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/12\">",
"      Pron G, Mocarski E, Bennett J, et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005; 105:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/13\">",
"      Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/14\">",
"      Ubaldi F, Tournaye H, Camus M, et al. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/15\">",
"      Hillis SD, Marchbanks PA, Peterson HB. Uterine size and risk of complications among women undergoing abdominal hysterectomy for leiomyomas. Obstet Gynecol 1996; 87:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/16\">",
"      Iverson RE Jr, Chelmow D, Strohbehn K, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996; 88:415.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Surgical alternatives to hysterectomy in the management of leiomyomas. ACOG practice bulletin 16. ACOG 2000; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/18\">",
"      Stotland NE, Lipschitz LS, Caughey AB. Delivery strategies for women with a previous classic cesarean delivery: a decision analysis. Am J Obstet Gynecol 2002; 187:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/19\">",
"      GARNET JD. UTERINE RUPTURE DURING PREGNANCY. AN ANALYSIS OF 133 PATIENTS. Obstet Gynecol 1964; 23:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/20\">",
"      Dubuisson JB, Fauconnier A, Deffarges JV, et al. Pregnancy outcome and deliveries following laparoscopic myomectomy. Hum Reprod 2000; 15:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/21\">",
"      Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004; 104:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/22\">",
"      Vercellini P, Maddalena S, De Giorgi O, et al. Determinants of reproductive outcome after abdominal myomectomy for infertility. Fertil Steril 1999; 72:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/23\">",
"      Marchionni M, Fambrini M, Zambelli V, et al. Reproductive performance before and after abdominal myomectomy: a retrospective analysis. Fertil Steril 2004; 82:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/24\">",
"      Saleh S, Issa A. Reproductive outcome after abdominal myomectomy. J Obstet Gynaecol 2000; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/25\">",
"      Gavai M, Berkes E, Lazar L, et al. Factors affecting reproductive outcome following abdominal myomectomy. J Assist Reprod Genet 2007; 24:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/26\">",
"      Dubuisson JB, Fauconnier A, Fourchotte V, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod 2001; 16:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/27\">",
"      Nezhat C. The \"cons\" of laparoscopic myomectomy in women who may reproduce in the future. Int J Fertil Menopausal Stud 1996; 41:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/28\">",
"      Hockstein S. Spontaneous uterine rupture in the early third trimester after laparoscopically assisted myomectomy. A case report. J Reprod Med 2000; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/29\">",
"      Seracchioli R, Manuzzi L, Vianello F, et al. Obstetric and delivery outcome of pregnancies achieved after laparoscopic myomectomy. Fertil Steril 2006; 86:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/30\">",
"      Goldfarb HA. Myoma coagulation (myolysis). Obstet Gynecol Clin North Am 2000; 27:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/31\">",
"      Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc 2002; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30662/abstract/32\">",
"      Cowan BD. Myomectomy and MRI-directed cryotherapy. Semin Reprod Med 2004; 22:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5466 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30662=[""].join("\n");
var outline_f29_60_30662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASYMPTOMATIC LEIOMYOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRECONCEPTIONAL PLANNING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INFERTILITY AND MISCARRIAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preparing for in vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OPTIONS FOR TREATMENT OF LEIOMYOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Myomectomy versus embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Route of myomectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Abdominal myomectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Miscellaneous techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12346?source=related_link\">",
"      Abdominal myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22473?source=related_link\">",
"      Uterine leiomyoma (fibroid) embolization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_60_30663="Positive end-expiratory pressure (PEEP)";
var content_f29_60_30663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Positive end-expiratory pressure (PEEP)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Rommel Sagana, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30663/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/60/30663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive end-expiratory pressure (PEEP) is the alveolar pressure above atmospheric pressure that exists at the end of expiration. There are two types of PEEP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PEEP that is provided by a mechanical ventilator is referred to as applied PEEP (also called extrinsic PEEP)",
"     </li>",
"     <li>",
"      PEEP that is secondary to incomplete expiration is referred to as auto-PEEP (also called intrinsic PEEP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical aspects of PEEP are discussed in this topic review. The strategy of high PEEP that has been investigated in patients with acute lung injury or acute respiratory distress syndrome is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link&amp;anchor=H11#H11\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'High PEEP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPLIED (EXTRINSIC) PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applied PEEP is usually one of the first ventilator settings chosen when mechanical ventilation is initiated. It is set directly on the ventilator. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of mechanical ventilation\", section on 'Initiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11865118\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small amount of applied PEEP (3 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) is occasionally referred to as physiologic PEEP, while higher levels are called supraphysiologic PEEP.",
"   </p>",
"   <p>",
"    Physiologic PEEP is indicated for most patients undergoing mechanical ventilation, since it mitigates end-expiratory alveolar collapse (a consequence of the endotracheal tube bypassing the glottic apparatus) and may reduce the incidence of ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The latter was demonstrated by a trial that randomly assigned 131 non-hypoxemic",
"    <span class=\"nowrap\">",
"     (PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    &gt;250) patients undergoing mechanical ventilation to receive either applied PEEP at 5 to 8 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or no applied PEEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/2\">",
"     2",
"    </a>",
"    ]. Within the applied PEEP group, 85 percent of the patients received 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of applied PEEP and 15 percent received 8 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. The applied PEEP group had a significantly lower incidence of ventilator-associated pneumonia (9 versus 25 percent) and was significantly less likely to develop hypoxemia (19 versus 54 percent). There were no differences in mortality, length of ICU stay, or length of hospital stay. Applied PEEP is associated with decreased leakage of posterior pharyngeal secretions into the lower airway, providing a potential mechanism for this benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supraphysiological PEEP is indicated for most patients with acute respiratory distress syndrome (ARDS). The benefits, harms, and application of supraphysiological PEEP in this clinical setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link&amp;anchor=H11#H11\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'High PEEP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=see_link&amp;anchor=H25#H25\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supraphysiologic PEEP is used selectively in other clinical situations, since the benefits are uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute respiratory distress syndrome (ARDS) and other types of hypoxemic respiratory failure &ndash; Supraphysiologic PEEP has been shown to improve physiological outcomes, such as oxygenation and ventilator-associated lung injury, but has not been consistently shown to improve clinical outcomes (eg, mortality, duration of mechanical ventilation, duration of ICU stay). A representative trial randomly assigned patients with ARDS to have their applied PEEP and FiO",
"      <sub>",
"       2",
"      </sub>",
"      adjusted according to either esophageal pressure measurements or a table of allowable combinations of applied PEEP and FiO",
"      <sub>",
"       2",
"      </sub>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/4\">",
"       4",
"      </a>",
"      ]. The group guided by esophageal pressure measurements was managed with significantly higher total PEEP (18 versus 12 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) and had a significantly higher",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio (280 versus 191 mmHg) at 72 hours. The 28-day mortality rate was also lower in the esophageal pressure group, but this failed to reach statistical significance (17 versus 39 percent, adjusted relative risk 0.46, 95% CI 0.19 to 1.00). Improved oxygenation due to supraphysiologic PEEP may be due to lung re-aeration according to an ultrasound study that showed that a PEEP-induced increase in PaO",
"      <sub>",
"       2",
"      </sub>",
"      correlated with lung ultrasound re-aeration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiogenic pulmonary edema &ndash; Supraphysiologic PEEP has been used in patients with cardiogenic pulmonary edema to improve cardiac function. However, the data indicate that supraphysiologic PEEP provides little additional benefit beyond the positive pressure ventilation alone. This was illustrated by a trial of 12 patients receiving mechanical ventilation, during which left ventricular performance was assessed by echocardiography before and after applied PEEP was increased by 10 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/6\">",
"       6",
"      </a>",
"      ]. Left ventricular performance did not change when applied PEEP was increased.",
"     </li>",
"     <li>",
"      Postoperative patients &ndash; Supraphysiologic PEEP has been employed in postoperative patients in an effort to prevent atelectasis; however, the strategy has not been shown to improve outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with auto-PEEP &ndash; Applied PEEP can decrease auto-PEEP in patients who have an expiratory flow limitation. This is discussed in greater detail below. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other &ndash; Supraphysiologic PEEP has also been used in patients with flail chest (to stabilize the chest wall) or tracheobronchomalacia (to maintain patency of the airways during expiration) with mixed results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to applied PEEP. However, applied PEEP can have adverse consequences (especially at high levels) and should be used cautiously in patients who have intracranial abnormalities, unilateral or focal lung disease, hypotension, hypovolemia, pulmonary embolism, dynamic hyperinflation without airflow limitation, or a bronchopleural fistula. It may also have undesirable consequences in patients undergoing prone ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Intracranial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intrathoracic pressure due to applied PEEP could theoretically decrease cerebral venous outflow, leading to increased intracranial pressure, decreased mean arterial pressure, or both. The end result may be decreased cerebral perfusion pressure and neurologic deterioration.",
"   </p>",
"   <p>",
"    Whether this actually occurs is uncertain. Observational studies with patients who had acute stroke or acute subarachnoid hemorrhage found that incremental elevation of applied PEEP was associated with diminished cerebral perfusion pressure (due to decreased mean arterial pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In contrast, another observational study with patients who had traumatic brain injury found that applied PEEP was associated with increased cerebral perfusion pressure (due to decreased intracranial pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/11\">",
"     11",
"    </a>",
"    ]. The reason for the conflicting results is uncertain, but may be related to varying effects of the different intracranial abnormalities.",
"   </p>",
"   <p>",
"    Given the uncertainty that exists, it is prudent to monitor both the mean arterial blood pressure and intracranial pressure (if available) whenever applied PEEP is used in a patient with an intracranial abnormality. Reduction of applied PEEP should be considered if the mean arterial blood pressure decreases or intracranial pressure increases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Focal lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applied PEEP can worsen hypoxemia in patients with focal lung disease (eg, pneumonia). This probably occurs because the applied PEEP compresses intraalveolar capillaries in the uninvolved lung, diverting blood flow to the injured lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/12\">",
"     12",
"    </a>",
"    ]. This increases intrapulmonary shunting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation increases intrathoracic pressure, which can decrease venous return, reduce cardiac output, and potentially cause hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/13\">",
"     13",
"    </a>",
"    ]. This is exacerbated by applied PEEP, especially in hypovolemic patients. In euvolemic patients, applied PEEP up to 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O is generally well tolerated from a hemodynamic standpoint, as demonstrated by a trial of eight patients with ARDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/14\">",
"     14",
"    </a>",
"    ]. Incremental increases of applied PEEP from 10 to 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O caused hypotension in only one patient, while gastric mucosal perfusion (a marker of systemic hypoperfusion) and cardiac index were unchanged in the remaining patients. A technique is being developed that estimates the cardiac output from changes in the pulmonary shunt at different levels of PEEP; the technique is not yet available for routine clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hyperinflation without flow limitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applied PEEP should not be used to treat auto-PEEP that exists in the absence of an expiratory flow limitation. Applied PEEP in this setting can worsen alveolar pressure and increase the risk of complications such as pulmonary barotrauma or hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10720758\">",
"    <span class=\"h3\">",
"     Prone patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are mechanically ventilated in the supine position, 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of applied PEEP is associated with similar redistribution of ventilation and blood flow to the dependent (ie, dorsal) portion of the lung, thereby maintaining a constant amount of ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, in patients who are mechanically ventilated in the prone ventilation, 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of applied PEEP is associated with a redistribution of blood flow to the dependent (ie, ventral) portion of the lung that is out of proportion to the redistribution of ventilation, thereby exacerbating the",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch. This suggests that supraphysiologic applied PEEP may be less beneficial, or potentially harmful, in patients undergoing prone ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AUTO (INTRINSIC) PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete expiration prior to the initiation of the next breath causes progressive air trapping (ie, dynamic hyperinflation). This accumulation of air increases alveolar pressure at the end of expiration, which is referred to as auto-PEEP.",
"   </p>",
"   <p>",
"    This section focuses on auto-PEEP that develops during mechanical ventilation. Auto-PEEP that develops during spontaneous breathing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36454?source=see_link\">",
"     \"Dynamic hyperinflation in patients with COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three common situations during which auto-PEEP develops: high minute ventilation, expiratory flow limitation, and expiratory resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     High minute ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high minute ventilation is caused by large tidal volumes, a high respiratory rate, or both. Either alteration can create auto-PEEP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large tidal volumes increase the volume that must be exhaled prior to the next breath. The larger the tidal volume, the less likely that the full tidal volume will be exhaled before the onset of the next breath.",
"     </li>",
"     <li>",
"      High respiratory rates decrease the duration of expiration. The faster the respiratory rate, the shorter the expiratory time and the less likely that the full tidal volume will be exhaled before the onset of the next breath.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Expiratory flow limitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An expiratory flow limitation exists when expiratory flow is slowed by airway narrowing due to collapse, bronchospasm, inflammation, or remodeling (",
"    <a class=\"graphic graphic_figure graphicRef77948 \" href=\"mobipreview.htm?10/27/10674\">",
"     figure 1",
"    </a>",
"    ). It increases the likelihood that the full tidal volume will not be exhaled before the onset of the next breath and auto-PEEP will develop.",
"   </p>",
"   <p>",
"    Most patients with chronic obstructive lung disease have an expiratory flow limitation, especially those with chronic obstructive airways disease (COPD). As a result, such patients are prone to developing auto-PEEP when mechanical ventilation is initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient's expiratory flow limitation is not routinely assessed in critical care units because it requires neuromuscular paralysis, specialized techniques, or both to be measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, it appears that expiratory flow limitation is more prominent when patients are supine rather than semirecumbent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Expiratory resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expiratory resistance is conceptually similar to expiratory flow limitation in that it slows expiration and increases the likelihood that the full tidal volume will not be exhaled before the onset of the next breath. However, expiratory resistance is unrelated to the airways. Examples of expiratory resistance include a narrow diameter or kinked endotracheal tube, inspissated secretions, exhalation or PEEP valves, and patient-ventilator asynchrony. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of mechanical ventilation\", section on 'Asynchrony'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potential sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auto-PEEP increases intrathoracic pressure, which can decrease venous return, reduce cardiac output, and potentially cause hypotension. This is most pronounced in hypovolemic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auto-PEEP can also cause alveolar overdistension, increasing the likelihood of pulmonary barotrauma and ventilator-associated lung injury. Alveolar overdistension can also cause hypoxemia if",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch increases due to compression of adjacent pulmonary blood vessels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, auto-PEEP increases the work required for a patient to trigger a ventilator breath when pressure-triggering is being used. This is because the patient must generate enough negative pressure to overcome the trigger sensitivity plus the auto-PEEP, rather than the trigger sensitivity alone (",
"    <a class=\"graphic graphic_figure graphicRef64640 \" href=\"mobipreview.htm?17/34/17966\">",
"     figure 2",
"    </a>",
"    ). As an example, a patient whose auto-PEEP is 8 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and whose ventilator has a trigger sensitivity of -2 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O needs to generate -10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of negative pressure to trigger a breath. In contrast, a patient who has no auto-PEEP only needs to generate the -2 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of negative pressure that is necessary to overcome the trigger sensitivity. Inability to trigger breaths may cause patient-ventilator asynchrony, dyspnea, and insufficient ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of mechanical ventilation\", section on 'Trigger'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of mechanical ventilation\", section on 'Asynchrony'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auto-PEEP can be detected using ventilator-generated flow versus time graphs, or palpation plus auscultation of the chest. With flow versus time graphs, the upstroke that indicates inspiratory flow will begin before the expiration tracing reaches zero flow if auto-PEEP exists. With palpation and auscultation, inspiratory airflow will be heard before the expiratory airflow ceases. Palpation and auscultation can confirm that auto-PEEP is present, but it is unreliable for determining its absence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach exists that can quantitate the auto-PEEP. Specifically, the auto-PEEP is determined by measuring the end-expiratory alveolar pressure and then subtracting the applied PEEP:",
"   </p>",
"   <p>",
"    &nbsp;Auto-PEEP = end-expiratory alveolar pressure - applied PEEP",
"   </p>",
"   <p>",
"    The end-expiratory alveolar pressure is measured by applying an end-expiratory breath hold and reading the airway pressure directly from the ventilator during the breath hold. The applied PEEP is set on the ventilator.",
"   </p>",
"   <p>",
"    Auto-PEEP is difficult to quantitate accurately, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widespread airway closure in patients with severe asthma can falsely lower the end-expiratory alveolar pressure measurement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/22\">",
"       22",
"      </a>",
"      ]. As a result, marked dynamic hyperinflation and auto-PEEP may be unrecognized.",
"     </li>",
"     <li>",
"      Expiratory muscle activity in non-paralyzed patients can falsely elevate the end-expiratory alveolar pressure measurement (",
"      <a class=\"graphic graphic_figure graphicRef79638 \" href=\"mobipreview.htm?41/62/42989\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/23\">",
"       23",
"      </a>",
"      ]. This can lead to the inappropriate and potentially harmful treatment of presumed auto-PEEP. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second situation described above can be avoided by carefully palpating for the absence of expiratory muscle activity prior to measuring the end-expiratory alveolar pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/24\">",
"     24",
"    </a>",
"    ]. This coincides with the onset of inspiration because the expiratory muscle must relax in order for the inspiratory muscles to decrease intrathoracic pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steps should be taken to correct auto-PEEP as soon as it is identified. Initial efforts should focus on determining and treating the underlying cause. When auto-PEEP persists despite management of its underlying cause, applied PEEP may be helpful if the patient has an expiratory flow limitation.",
"   </p>",
"   <p>",
"    When a high minute ventilation is the presumed cause of auto-PEEP, the minute ventilation should be decreased by lowering the tidal volume or respiratory rate. This frequently requires a strategy of permissive hypercapnia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27127?source=see_link\">",
"     \"Permissive hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an expiratory flow limitation due to obstructive airways disease is the presumed cause of auto-PEEP, the duration of expiration should be prolonged. This can be accomplished by increasing the inspiratory flow, decreasing the tidal volume, or decreasing the respiratory rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8120?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with bronchodilators, steroids, and antibiotics may also be beneficial. In a study of 25 patients with COPD and acute respiratory failure, expiratory flow limitation was present in 96 percent of the patients at the initiation of mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/26\">",
"     26",
"    </a>",
"    ]. The prevalence of expiratory flow limitation decreased to 47 percent at the time of extubation and 40 percent at the time of ICU discharge, indicating that expiratory flow limitation may respond to therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When increased expiratory resistance is the presumed cause of auto-PEEP, the source of increased resistance should be identified and corrected. This may require sedation, pharmacologic paralysis, or replacement of the endotracheal tube or ventilator tubing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Applied PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small amounts of applied PEEP can decrease auto-PEEP in patients who have an expiratory flow limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. This can be conceptualized as the applied PEEP holding open the narrowed airways during expiration, improving expiratory airflow, and allowing more complete expiration prior to the onset of the next breath. Additional benefits of using applied PEEP to offset auto-PEEP include decreased oxygen consumption and improved gas exchange. The latter is due to opening the small airways in the dependent lung zones and distributing inspired gas more homogeneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Applied PEEP should always be less than the measured auto-PEEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/33\">",
"     33",
"    </a>",
"    ]. Otherwise, alveolar pressure may increase, placing the patient at increased risk for complications such as pulmonary barotrauma or hypotension (",
"    <a class=\"graphic graphic_figure graphicRef72568 \" href=\"mobipreview.htm?11/51/12094\">",
"     figure 4",
"    </a>",
"    ). One study even suggested that applied PEEP does not need to exceed the measured auto-PEEP for this to occur. Rather, it can occur if the applied PEEP is greater than 85 percent of the measured auto-PEEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/34\">",
"     34",
"    </a>",
"    ]. Given the potential inaccuracy of auto-PEEP measurements, it is prudent to set applied PEEP to a level that is less than 50 percent of the measured auto-PEEP.",
"   </p>",
"   <p>",
"    Applied PEEP should not be used to counter auto-PEEP in patients who do not have an expiratory flow limitation. Applied PEEP may increase alveolar pressure and increase the risk of both barotrauma and hemodynamic compromise in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30663/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive end-expiratory pressure (PEEP) is the alveolar pressure above atmospheric pressure that exists at the end of expiration. PEEP that is applied through a mechanical ventilator is referred to as applied PEEP (also called extrinsic PEEP), whereas PEEP that is secondary to incomplete exhalation is referred to as auto-PEEP (also called intrinsic PEEP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Applied PEEP",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small amount of applied PEEP (3 to 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) is used in most mechanically ventilated patients to mitigate end-expiratory alveolar collapse. (See",
"      <a class=\"local\" href=\"#H11865118\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A higher level of applied PEEP (&gt;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) is sometimes used to improve hypoxemia or reduce ventilator-associated lung injury in patients with acute lung injury, acute respiratory distress syndrome, or other types of hypoxemic respiratory failure. (See",
"      <a class=\"local\" href=\"#H11865118\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Applied PEEP is also used at varying levels to offset the effects of auto-PEEP in patients with an expiratory flow limitation. (See",
"      <a class=\"local\" href=\"#H11865118\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications to applied PEEP. However, applied PEEP can have adverse consequences (especially at high levels) and should be used cautiously in patients with intracranial abnormalities, unilateral or focal lung disease, hypotension, hypovolemia, dynamic hyperinflation without airflow limitation, or a bronchopleural fistula. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Auto-PEEP",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three common situations during which auto-PEEP develops: high minute ventilation, expiratory flow limitation, and expiratory resistance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Auto-PEEP increases intrathoracic pressure, which can decrease venous return, reduce cardiac output, and potentially cause hypotension. It can also cause alveolar overdistension, increasing the likelihood of pulmonary barotrauma and ventilator-associated lung injury. Finally, auto-PEEP increases the work required for a patient to trigger a ventilator breath if pressure-triggering is being used. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Potential sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Auto-PEEP can be detected using ventilator-generated flow versus time graphs or by palpation and auscultation of the chest. It can be detected and quantitated by measuring the end-expiratory alveolar pressure and then subtracting the applied PEEP. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Steps should be taken to correct auto-PEEP as soon as it is identified. Initial efforts should focus on determining and treating the underlying cause. When auto-PEEP persists despite management of its underlying cause, applied PEEP may be helpful if the patient has an expiratory flow limitation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with auto-PEEP and an expiratory flow limitation, we suggest administering applied PEEP at a level that is 50 percent of the measured auto-PEEP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/1\">",
"      Smith, RA. Physiologic PEEP. Respir Care 1988; 33:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/2\">",
"      Manzano F, Fern&aacute;ndez-Mond&eacute;jar E, Colmenero M, et al. Positive-end expiratory pressure reduces incidence of ventilator-associated pneumonia in nonhypoxemic patients. Crit Care Med 2008; 36:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/3\">",
"      Lucangelo U, Zin WA, Antonaglia V, et al. Effect of positive expiratory pressure and type of tracheal cuff on the incidence of aspiration in mechanically ventilated patients in an intensive care unit. Crit Care Med 2008; 36:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/4\">",
"      Talmor D, Sarge T, Malhotra A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med 2008; 359:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/5\">",
"      Bouhemad B, Brisson H, Le-Guen M, et al. Bedside ultrasound assessment of positive end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med 2011; 183:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/6\">",
"      Fellahi JL, Valtier B, Beauchet A, et al. Does positive end-expiratory pressure ventilation improve left ventricular function? A comparative study by transesophageal echocardiography in cardiac and noncardiac patients. Chest 1998; 114:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/7\">",
"      Good JT Jr, Wolz JF, Anderson JT, et al. The routine use of positive end-expiratory pressure after open heart surgery. Chest 1979; 76:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/8\">",
"      Wetterslev J, Hansen EG, Roikjaer O, et al. Optimizing peroperative compliance with PEEP during upper abdominal surgery: effects on perioperative oxygenation and complications in patients without preoperative cardiopulmonary dysfunction. Eur J Anaesthesiol 2001; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/9\">",
"      Georgiadis D, Schwarz S, Baumgartner RW, et al. Influence of positive end-expiratory pressure on intracranial pressure and cerebral perfusion pressure in patients with acute stroke. Stroke 2001; 32:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/10\">",
"      Muench E, Bauhuf C, Roth H, et al. Effects of positive end-expiratory pressure on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation. Crit Care Med 2005; 33:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/11\">",
"      Huynh T, Messer M, Sing RF, et al. Positive end-expiratory pressure alters intracranial and cerebral perfusion pressure in severe traumatic brain injury. J Trauma 2002; 53:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/12\">",
"      Hasan FM, Beller TA, Sobonya RE, et al. Effect of positive end-expiratory pressure and body position in unilateral lung injury. J Appl Physiol 1982; 52:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/13\">",
"      Pinsky MR. Cardiovascular issues in respiratory care. Chest 2005; 128:592S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/14\">",
"      Bruhn A, Hernandez G, Bugedo G, Castillo L. Effects of positive end-expiratory pressure on gastric mucosal perfusion in acute respiratory distress syndrome. Crit Care 2004; 8:R306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/15\">",
"      Sundaresan A, Chase JG, Hann CE, Shaw GM. Cardiac output estimation using pulmonary mechanics in mechanically ventilated patients. Biomed Eng Online 2010; 9:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/16\">",
"      Petersson J, Ax M, Frey J, et al. Positive end-expiratory pressure redistributes regional blood flow and ventilation differently in supine and prone humans. Anesthesiology 2010; 113:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/17\">",
"      Armaganidis A, Stavrakaki-Kallergi K, Koutsoukou A, et al. Intrinsic positive end-expiratory pressure in mechanically ventilated patients with and without tidal expiratory flow limitation. Crit Care Med 2000; 28:3837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/18\">",
"      Gay PC, Rodarte JR, Hubmayr RD. The effects of positive expiratory pressure on isovolume flow and dynamic hyperinflation in patients receiving mechanical ventilation. Am Rev Respir Dis 1989; 139:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/19\">",
"      Valta P, Corbeil C, Lavoie A, et al. Detection of expiratory flow limitation during mechanical ventilation. Am J Respir Crit Care Med 1994; 150:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/20\">",
"      Gurevitch MJ, Gelmont D. Importance of trigger sensitivity to ventilator response delay in advanced chronic obstructive pulmonary disease with respiratory failure. Crit Care Med 1989; 17:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/21\">",
"      Kress JP, O'Connor MF, Schmidt GA. Clinical examination reliably detects intrinsic positive end-expiratory pressure in critically ill, mechanically ventilated patients. Am J Respir Crit Care Med 1999; 159:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/22\">",
"      Leatherman JW, Ravenscraft SA. Low measured auto-positive end-expiratory pressure during mechanical ventilation of patients with severe asthma: hidden auto-positive end-expiratory pressure. Crit Care Med 1996; 24:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/23\">",
"      Lessard MR, Lofaso F, Brochard L. Expiratory muscle activity increases intrinsic positive end-expiratory pressure independently of dynamic hyperinflation in mechanically ventilated patients. Am J Respir Crit Care Med 1995; 151:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/24\">",
"      Zakynthinos SG, Vassilakopoulos T, Zakynthinos E, Roussos C. Accurate measurement of intrinsic positive end-expiratory pressure: how to detect and correct for expiratory muscle activity. Eur Respir J 1997; 10:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/25\">",
"      Brochard L. Intrinsic (or auto-) positive end-expiratory pressure during spontaneous or assisted ventilation. Intensive Care Med 2002; 28:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/26\">",
"      Alvisi V, Romanello A, Badet M, et al. Time course of expiratory flow limitation in COPD patients during acute respiratory failure requiring mechanical ventilation. Chest 2003; 123:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/27\">",
"      Smith TC, Marini JJ. Impact of PEEP on lung mechanics and work of breathing in severe airflow obstruction. J Appl Physiol 1988; 65:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/28\">",
"      Kondili E, Alexopoulou C, Prinianakis G, et al. Pattern of lung emptying and expiratory resistance in mechanically ventilated patients with chronic obstructive pulmonary disease. Intensive Care Med 2004; 30:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/29\">",
"      Caramez MP, Borges JB, Tucci MR, et al. Paradoxical responses to positive end-expiratory pressure in patients with airway obstruction during controlled ventilation. Crit Care Med 2005; 33:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/30\">",
"      Rossi A, Santos C, Roca J, et al. Effects of PEEP on VA/Q mismatching in ventilated patients with chronic airflow obstruction. Am J Respir Crit Care Med 1994; 149:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/31\">",
"      Guerin C, LeMasson S, de Varax R, et al. Small airway closure and positive end-expiratory pressure in mechanically ventilated patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/32\">",
"      Gl&eacute;rant JC, Leleu O, Rose D, et al. Oxygen consumption and PEEPe in ventilated COPD patients. Respir Physiol Neurobiol 2005; 146:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/33\">",
"      Tuxen DV. Detrimental effects of positive end-expiratory pressure during controlled mechanical ventilation of patients with severe airflow obstruction. Am Rev Respir Dis 1989; 140:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/34\">",
"      Ranieri VM, Giuliani R, Cinnella G, et al. Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation. Am Rev Respir Dis 1993; 147:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30663/abstract/35\">",
"      Marini JJ. Should PEEP be used in airflow obstruction? Am Rev Respir Dis 1989; 140:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1642 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30663=[""].join("\n");
var outline_f29_60_30663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPLIED (EXTRINSIC) PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11865118\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Intracranial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Focal lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hyperinflation without flow limitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10720758\">",
"      - Prone patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AUTO (INTRINSIC) PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - High minute ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Expiratory flow limitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Expiratory resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potential sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Applied PEEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Applied PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Auto-PEEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1642|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/27/10674\" title=\"figure 1\">",
"      Auto PEEP and hyperinflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/34/17966\" title=\"figure 2\">",
"      Auto PEEP trigger threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/62/42989\" title=\"figure 3\">",
"      Corrected intrinsic PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/51/12094\" title=\"figure 4\">",
"      External PEEP with auto PEEP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36454?source=related_link\">",
"      Dynamic hyperinflation in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/59/8120?source=related_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_60_30664="Paraneoplastic pemphigus histopathology";
var content_f29_60_30664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Suprabasal acantholysis in paraneoplastic pemphigus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30664=[""].join("\n");
var outline_f29_60_30664=null;
var title_f29_60_30665="Normal liver formalin fixation";
var content_f29_60_30665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal liver formalin fixation (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A surgically-obtained wedge resection of liver. Note that hepatocytes swell in formalin fixation, and sinusoids are more difficult to recognize than in Carnoy's fixation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30665=[""].join("\n");
var outline_f29_60_30665=null;
var title_f29_60_30666="Assessment and management of dyspnea in palliative care";
var content_f29_60_30666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of dyspnea in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Deborah Dudgeon, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Joshua Shadd, MD, CCFP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     J  Andrew Billings, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Eduardo Bruera, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/60/30666/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/60/30666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H89103965\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is a term used to characterize a subjective experience of breathing discomfort that is comprised of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors that may induce secondary physiological and behavioral responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dyspnea, or breathlessness, encompasses multiple somatic perceptions that are variously described as air hunger, increased effort of breathing, chest tightness, rapid breathing, incomplete exhalation, or a feeling of suffocation. Dyspnea is a multidimensional symptom, consisting of affective as well as physical aspects. Its presence and severity cannot be inferred from physical examination or laboratory investigations &ndash; we must ask about it. It can occur in the absence of physical signs (eg, rapid, deep, or labored breathing) or abnormal findings on investigations such as blood gases or chest radiographs.",
"   </p>",
"   <p>",
"    Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients and their families facing life-threatening or other serious illnesses. &nbsp;The primary tenets of palliative care are symptom management; establishing goals of care that are in keeping with the patient&rsquo;s values and preferences; consistent and sustained communication between the patient and all those involved in his or her care; psychosocial, spiritual, and practical support both to patients and their family caregivers, and coordination across sites of care. Palliative care aims to relieve suffering in all stages of disease and is not limited to end of life care. Within an integrated model of medical care, palliative care is provided at the same time as curative or life-prolonging treatments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic focuses on the assessment and care of patients with advanced terminal illness who develop dyspnea. An approach to the diagnosis of dyspnea in adults and the management of specific causes of dyspnea are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=see_link&amp;anchor=H5#H5\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\", section on 'Respiratory management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link&amp;anchor=H11#H11\">",
"     \"End of life considerations for heart failure patients\", section on 'Dyspnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804717\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89103972\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is common in patients with advanced life-threatening illness of all types (",
"    <a class=\"graphic graphic_table graphicRef60535 \" href=\"mobipreview.htm?41/5/42076\">",
"     table 1",
"    </a>",
"    ). It is one of the most common symptoms reported in patients with a terminal cancer in the last six months of life (",
"    <a class=\"graphic graphic_figure graphicRef59669 \" href=\"mobipreview.htm?34/45/35537\">",
"     figure 1",
"    </a>",
"    ). In a systematic review of the prevalence of 11 symptoms in patients with advanced illness from any of five diagnoses (cancer, AIDS, heart disease, chronic obstructive pulmonary disease [COPD] or renal disease), dyspnea was one of only three symptoms to be present in &gt;50 percent of patients from all five groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/2\">",
"     2",
"    </a>",
"    ]. Regardless of diagnosis, both the prevalence and severity of dyspnea tend to increase over time, particularly in the last six months of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89103979\">",
"    <span class=\"h2\">",
"     Psychological and social impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is a major detriment to quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. It has been identified as the most important variable influencing the will to live among terminally ill cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/8\">",
"     8",
"    </a>",
"    ] and the second most common reason to initiate palliative sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Dyspneic patients frequently report social isolation as a consequence of reduced activity levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of managing common non-pain symptoms in palliative care\", section on 'Palliative sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89103986\">",
"    <span class=\"h2\">",
"     Prognostic significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea is a symptom that is associated with shortened survival in a variety of diseases, particularly terminally ill cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/3,14-18\">",
"     3,14-18",
"    </a>",
"    ]. One study found that the presence of dyspnea was associated with a median survival of less than 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=see_link&amp;anchor=H6#H6\">",
"     \"Survival estimates in advanced terminal cancer\", section on 'Clinical signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89103993\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CAUSES OF DYSPNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurophysiology of dyspnea is related to but distinct from the control of ventilation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8839?source=see_link\">",
"     \"Physiology of dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dyspnea is the perception that the respiratory muscle response is inadequate or unsustainable. This perception arises from the sensory cortex, which integrates information from multiple sources including peripheral and central chemoreceptors, mechanoreceptors (arising from large airways, lung parenchyma and the chest wall) and respiratory motor centers (in the medulla as well as motor cortex). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8839?source=see_link\">",
"     \"Physiology of dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dyspnea may arise from increased ventilatory demand, impairment of the mechanical process of ventilation, or both. Specific causes and potential palliative interventions in this population are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104000\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF DYSPNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of a formal assessment of dyspnea in palliative care are to understand the intensity, distress, and functional impact of dyspnea, to diagnose potentially reversible contributing factors, and to monitor the response to interventions. Common causes of dyspnea in palliative care with potential palliative interventions are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"     table 2",
"    </a>",
"    ). The evaluation of dyspnea depends on its acuity; general approaches to undiagnosed acute and chronic dyspnea are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the patient with dyspnea\", section on 'Evaluation of acute dyspnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the patient with dyspnea\", section on 'Evaluation of chronic dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for dyspnea with a validated symptom assessment tool, such as the Memorial symptom assessment scale, short form (MSAS-SF, (",
"    <a class=\"graphic graphic_figure graphicRef60205 \" href=\"mobipreview.htm?23/13/23762\">",
"     figure 2",
"    </a>",
"    )), or the Edmonton Symptom Assessment scale (",
"    <a class=\"graphic graphic_table graphicRef56065 \" href=\"mobipreview.htm?25/43/26299\">",
"     table 3",
"    </a>",
"    ), is a first step in recognizing the presence of dyspnea, but not its specific characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Assessment and rating instruments for symptoms'",
"    </a>",
"    .) There is no clinical &ldquo;gold-standard&rdquo; assessment tool, and no single instrument assesses concurrently for intensity (how severe is your dyspnea?), functional impact (how limiting is the dyspnea?) and distress (how bothersome is the dyspnea?) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to symptom assessment in palliative care\", section on 'Assessment and rating instruments for symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104007\">",
"    <span class=\"h2\">",
"     Quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients employ a variety of terms to describe their sensation of breathlessness. Certain descriptors tend to cluster with certain diagnoses (eg, &ldquo;air hunger&rdquo; and &ldquo;feeling of suffocation&rdquo; for heart failure versus &ldquo;incomplete exhalation&rdquo; and &ldquo;chest tightness&rdquo; for asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/22\">",
"     22",
"    </a>",
"    ]), suggesting that different disease processes, causing distinct pathophysiologic abnormalities, produce qualitatively distinguishable sensations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/23\">",
"     23",
"    </a>",
"    ]. Dyspnea questionnaires utilizing lists of descriptive phrases have shown some benefit in facilitating diagnosis in the clinical setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/24\">",
"     24",
"    </a>",
"    ], but have not found widespread application, perhaps because many patients have multiple, concurrent physiologic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the patient with dyspnea\", section on 'Language of dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104014\">",
"    <span class=\"h2\">",
"     Intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used tools for measuring the intensity of dyspnea in the clinical setting are numeric rating scales (0 to 10) and visual analogue scales (0 to 100 mm). The modified Borg scale (",
"    <a class=\"graphic graphic_table graphicRef63981 \" href=\"mobipreview.htm?15/10/15532\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/25\">",
"     25",
"    </a>",
"    ] assigns verbal descriptors to numerical values between zero and ten and is a popular tool to assess the intensity of dyspnea in the research literature.",
"   </p>",
"   <p>",
"    Clinicians and family members should assess dyspnea by asking patients how short of breath they feel, rather than estimating their degree of dyspnea from the perceived degree of respiratory effort (eg, tachypnea, accessory muscle use). Occasionally patients who have moderate to severe tachypnea will not have dyspnea. In contrast, patients who are not tachypneic may report severe dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104021\">",
"    <span class=\"h2\">",
"     Functional impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breathless patients inevitably reduce their activity level to accommodate dyspnea, so questions about limitations in performing specific activities can be used to assess the impact of dyspnea. The Oxygen Cost Diagram (",
"    <a class=\"graphic graphic_figure graphicRef64769 \" href=\"mobipreview.htm?43/31/44542\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/26\">",
"     26",
"    </a>",
"    ] asks patients to identify the level of activity they are unable to perform due to dyspnea, giving clinicians valuable information regarding the functional impact of the symptom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104028\">",
"    <span class=\"h2\">",
"     Distress caused by dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distress caused by a symptom arises not only from the symptom&rsquo;s intensity, but also from other factors such as the functional impact and meaning of that symptom for the patient (which can be influenced by personality type, past experiences, coping mechanisms, etc). Acute episodes of breathlessness are usually accompanied by feelings of anxiety, fear, and possibly panic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients express fear of dying during an acute episode or when waking in the middle of the night with intense air hunger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the patient with dyspnea\", section on 'Evaluation of acute dyspnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the patient with dyspnea\", section on 'Evaluation of chronic dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scales are available that permit an assessment of the amount of distress caused by dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. One such instrument is depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60205 \" href=\"mobipreview.htm?23/13/23762\">",
"     figure 2",
"    </a>",
"    ). However, many palliative care patients are in acute or severe distress and cannot use scales as an assessment tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31015989\">",
"    <span class=\"h2\">",
"     Dyspnea and psychological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;People&rsquo;s perception of the intensity of breathlessness can be affected by psychological factors, such as anxiety and depression. In a number of studies, anxiety is significantly correlated with the intensity of dyspnea but the correlations are low and only explain 9 percent of the variance in the intensity of breathlessness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/32-37\">",
"     32-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression scores alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/32\">",
"     32",
"    </a>",
"    ] and in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/37\">",
"     37",
"    </a>",
"    ] with anxiety scores are also significantly correlated with the intensity of dyspnea. One study found that depression, not anxiety, was significantly correlated in univariate and multivariate analysis with the effect of dyspnea on the person&rsquo;s activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the relative roles of depression and anxiety may depend on the duration and severity of dyspnea. One study found that patients had higher levels of anxiety during high or medium, as compared with lower levels of breathlessness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/38\">",
"     38",
"    </a>",
"    ]. This study supports the view that anxiety is probably a more prominent factor than depression during acute episodes of breathlessness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link&amp;anchor=H20#H20\">",
"     \"Psychosocial issues at the end of life\", section on 'Anxiety'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104035\">",
"    <span class=\"h2\">",
"     Role of investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing and imaging studies (pulse oximetry, arterial blood gases, chest x-rays, pulmonary function tests, etc) are not helpful in detecting the presence or severity of dyspnea. Such investigations can, however, help determine the cause of a patient&rsquo;s breathlessness and guide the choice of treatment interventions (",
"    <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104042\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate goal in treating any symptom is to reduce the distress it causes. Among patients receiving palliative care for advanced terminal illness, the causes of dyspnea are often untreatable. However, if a specific treatable cause of dyspnea is found (eg, bronchospasm, pulmonary emboli, upper airway obstruction, pleural effusion), specific treatment of that process may be appropriate depending on the invasiveness of the therapy and the patient&rsquo;s values and preferences (",
"    <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"     table 2",
"    </a>",
"    ). Management of these specific underlying causes of dyspnea is beyond the scope of this topic review and is covered in individual topic reviews. This section will focus on nonpharmacologic and pharmacologic treatments that are aimed directly at the symptom of breathlessness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104049\">",
"    <span class=\"h2\">",
"     Nonpharmacologic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidisciplinary approach to dyspnea that addresses various pathophysiological factors from symptom production to perception and interpretation of the symptom is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef74531 \" href=\"mobipreview.htm?37/34/38443\">",
"     table 5",
"    </a>",
"    ). Nurses (education), physiotherapists (exercise therapy), respiratory therapists, occupational therapists (ergonomics and accommodation strategies), dieticians (to optimize nutrition), and",
"    <span class=\"nowrap\">",
"     psychologist/chaplains",
"    </span>",
"    (to address symptom meaning) all have important roles to play [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404055\">",
"    <span class=\"h3\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;General supportive measures used to alleviate dyspnea include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relaxation techniques and psychosocial support [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Modification in activity level and the use of bathroom aids and wheelchairs to increase the autonomy of patients and their families.",
"     </li>",
"     <li>",
"      Use of a fan with cool air blowing on the face [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/42-45\">",
"       42-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chest wall and intrapulmonary percussive vibration and mechanical insufflation-exsufflation devices can be helpful for patients who have difficulty mobilizing secretions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935168\">",
"    <span class=\"h3\">",
"     Pulmonary rehabilitation and respiratory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence to support relief of dyspnea by pulmonary rehabilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], although most studies include primarily or exclusively patients with COPD. Pulmonary rehabilitation includes exercise training, psychosocial support, nutrition therapy, and self-management strategies, such as diaphragmatic and pursed lip breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/49\">",
"     49",
"    </a>",
"    ]. Pulmonary rehabilitation may also improve exercise tolerance and psychological parameters among patients with lung cancer, although results are preliminary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/50\">",
"     50",
"    </a>",
"    ]. Pulmonary rehabilitation might not be appropriate for patients with a short estimated life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935678\">",
"    <span class=\"h3\">",
"     Oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of supplemental oxygen for relief of dyspnea have shown mixed results in hypoxemic patients with cancer and severe lung disease; no study has suggested benefit for nonhypoxemic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/51\">",
"     51",
"    </a>",
"    ]. Studies of supplemental oxygen for dyspnea in advanced cancer are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef51877 \" href=\"mobipreview.htm?11/5/11358\">",
"     table 6",
"    </a>",
"    ). Based upon moderate quality of evidence, evidence-based guidelines from the American College of Physicians (ACP) recommend oxygen for short-term relief of hypoxemia in adults with dyspnea and serious illness at the end of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2802076\">",
"     'Recommendations of expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A systematic review of controlled trials of oxygen therapy for dyspnea in a mixture of hypoxemic and non-hypoxemic adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/54\">",
"     54",
"    </a>",
"    ] included three trials conducted in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], three trials of patients with cardiac failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/58-60\">",
"     58-60",
"    </a>",
"    ], and one of patients with kyphoscoliosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/61\">",
"     61",
"    </a>",
"    ]. The authors concluded that there was no consistent benefit for oxygen over air inhalation for dyspnea due to end stage cancer or cardiac failure, although the number of trials was small. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link&amp;anchor=H4#H4\">",
"     \"Long-term supplemental oxygen therapy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935686\">",
"    <span class=\"h4\">",
"     Patients with hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen is a standard therapy for symptomatic management of patients who are hypoxemic on room air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/52,62\">",
"     52,62",
"    </a>",
"    ]. However, the presence of hypoxemia does not reliably predict symptomatic response from oxygen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55,63\">",
"     55,63",
"    </a>",
"    ]. Studies of supplemental oxygen for relief of dyspnea have shown mixed results in hypoxemic patients with cancer and severe lung disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two studies addressing the role of oxygen supplementation for dyspnea in hypoxemic patients with advanced cancer patients are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef51877 \" href=\"mobipreview.htm?11/5/11358\">",
"       table 6",
"      </a>",
"      ). In one study, a single patient was administered oxygen or compressed air in a randomized and blinded fashion and repeatedly reported greater relief with oxygen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/64\">",
"       64",
"      </a>",
"      ]. In the second cross-over study of 14 terminally ill cancer patients with hypoxemic dyspnea, administration of oxygen at 5",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      by face mask was associated with a significant improvement in a dyspnea visual analog scale compared with air treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other cross-over studies in patients with advanced cancer included both hypoxemic and nonhypoxemic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55,63\">",
"       55,63",
"      </a>",
"      ]. In one of the studies, similar degrees of improvement occurred with air and oxygen treatment; baseline oxygen saturation did not predict greater improvement with oxygen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55\">",
"       55",
"      </a>",
"      ]. In the other study, there was no difference between air and oxygen treatment in patient preference or in dyspnea, as measured by a visual analog scale (VAS); there was also no correlation between oxygen saturation and dyspnea score (VAS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of the three trials that have evaluated the short-term effects of supplemental oxygen therapy on breathlessness at rest in patients with advanced lung disease, two report significant improvement in dyspnea with oxygen therapy versus air flow through nasal cannula or mouthpiece [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/65,66\">",
"       65,66",
"      </a>",
"      ], while a third did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The perceived benefit of oxygen therapy in terminally ill patients with dyspnea extends beyond its ability to reverse hypoxemia; some patients report lessened dyspnea despite unrelieved hypoxemia. Although there is a likely a placebo effect of oxygen and the medical symbolism inherent in its administration, there may be other reasons for this perceived benefit (",
"    <a class=\"graphic graphic_table graphicRef54116 \" href=\"mobipreview.htm?4/45/4827\">",
"     table 7",
"    </a>",
"    ). Several studies support the hypothesis that stimulation of the trigeminal nerve (V2 branch) has a central inhibitory effect on dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/42,67\">",
"     42,67",
"    </a>",
"    ]. Thus, part of the effect of oxygen may be attributed to sensory stimulation, and, as noted above, might be duplicated by the application of cool moving air to the face. (See",
"    <a class=\"local\" href=\"#H89104049\">",
"     'Nonpharmacologic management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935693\">",
"    <span class=\"h4\">",
"     Non-hypoxemic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are not hypoxemic, supplemental oxygen appears no more likely than room air to provide relief of dyspnea. Of the five studies that enrolled non-hypoxemic patients with advanced cancer (",
"    <a class=\"graphic graphic_table graphicRef51877 \" href=\"mobipreview.htm?11/5/11358\">",
"     table 6",
"    </a>",
"    ), none showed a statistically significant benefit for oxygen supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55-57,63,64,68,69\">",
"     55-57,63,64,68,69",
"    </a>",
"    ]. As an example, a multinational, randomized trial of 239 patients found no difference between oxygen and room air via nasal cannulae for the treatment of refractory dyspnea in non-hypoxemic adult outpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935714\">",
"    <span class=\"h3\">",
"     Noninvasive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) refers to positive pressure ventilation that is delivered through a noninvasive interface (nasal mask, facemask, or nasal plugs), rather than an invasive interface (endotracheal tube, tracheostomy). NPPV can be delivered using a standard ventilator or a portable ventilator (eg, a pressure support ventilator that provides bilevel positive airway pressure [BPAP]). Clinical benefit has been most strongly demonstrated in acute respiratory acidosis in exacerbations of COPD, hypoxemia from cardiogenic pulmonary edema, hypoxemic respiratory failure in the immunocompromised host, and in patients with advanced neuromuscular disorders such as amyotrophic lateral sclerosis (ALS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=see_link&amp;anchor=H8#H8\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\", section on 'Noninvasive positive pressure ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NPPV may be considered as a palliative measure in dying patients who have severe dyspnea and have decided to forego life-prolonging therapies and focus only on comfort measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/70\">",
"     70",
"    </a>",
"    ]. In this setting, NPPV can be used with the intent of reducing the work of breathing, easing dyspnea, and helping to maintain wakefulness by reducing the amount of opioids needed to maintain comfort. NPPV can also be used to prolong life to meet a patient&rsquo;s short-term goals (eg, allowing time for the family to visit) while providing for a comfortable death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/71\">",
"     71",
"    </a>",
"    ]. Occasionally, NPPV may be used to manage an episode of acute, reversible respiratory failure in a patient who has an advanced serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness and wishes to avoid invasive mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    There is much variability in practice and attitudes regarding the use of NPPV at the end of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/73\">",
"     73",
"    </a>",
"    ]. Limited data are available about the use of NPPV to alleviate dyspnea in this setting, its tolerability, and whether or not it is opioid-sparing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/74\">",
"     74",
"    </a>",
"    ]. The available data can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 200 hospitalized patients with end-stage cancer and severe respiratory failure, NPPV was shown to improve dyspnea much faster than passive oxygen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/75\">",
"       75",
"      </a>",
"      ]. In addition, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      needed to control dyspnea was significantly less in the NPPV group. Further study is needed to assess outcomes such as survival, duration of mask tolerance, and quality of life.",
"     </li>",
"     <li>",
"      Observational data show that among patients with &ldquo;do not intubate&rdquo; orders and acute respiratory failure, the use of NPPV is associated with a 35 to 45 percent chance of survival to hospital discharge with higher survival rates for patients with COPD or heart failure as a cause of the respiratory failure than for those with cancer or pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to questions as to its effectiveness in patients receiving end of life care, NPPV is noisy and can be uncomfortable and frightening. Patient tolerance of the face mask is crucial to the success of NPPV. Decreased mental status may be considered a contraindication to NPPV because of the risk of aspiration.",
"   </p>",
"   <p>",
"    The cost and experience needed to implement NPPV generally limit its initiation to the hospital setting, with some exceptions. While NPPV can be used at home or at a hospice facility, it requires adequate nursing, respiratory therapy, and physician support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of NPPV in the palliative setting remains a controversial area of clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/78\">",
"     78",
"    </a>",
"    ]. If a trial of NPPV is being considered, it is essential to clearly establish in advance the goals of the intervention, a timeframe for reevaluation, and markers of success or lack thereof. Patients and families should understand that the dying process may be prolonged by the use of NPPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/78\">",
"     78",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935721\">",
"    <span class=\"h3\">",
"     Airway debulking and stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with dyspnea due to central airway obstruction from a tumor, debulking of the tumor with endobronchial techniques, such as endoscopic laser, electrocautery, argon plasma coagulation, and cryotherapy, followed by placement of an airway stent may provide palliation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/79\">",
"     79",
"    </a>",
"    ]. One report described two patients with substantial improvement in dyspnea after stent placement, although survival was brief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/80\">",
"     80",
"    </a>",
"    ]. Metallic stents can be introduced via flexible bronchoscopy under conscious sedation. The role of endoscopic laser, electrocautery, and stent placement in managing central airway obstruction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Airway interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5403980\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     <strong>",
"      Helium/oxygen",
"     </strong>",
"    </span>",
"    &mdash; The lower density of",
"    <span class=\"nowrap\">",
"     helium/oxygen",
"    </span>",
"    combinations (relative to",
"    <span class=\"nowrap\">",
"     nitrogen/oxygen)",
"    </span>",
"    promotes laminar flow and enables greater alveolar ventilation at a given inspiratory pressure, thus diminishing the work of breathing.",
"    <span class=\"nowrap\">",
"     Helium/oxygen",
"    </span>",
"    (HEO",
"    <sub>",
"     2",
"    </sub>",
"    , Heliox) is therefore a potentially attractive alternative for patients with dyspnea from partial airway obstruction, impaired ability to generate inspiratory pressure, or both. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in non-hypoxemic, exercising patients with either lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/56\">",
"     56",
"    </a>",
"    ]",
"    <sup>",
"    </sup>",
"    or COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/81-83\">",
"     81-83",
"    </a>",
"    ] have found that a Heliox is superior to room air for exercise tolerance and dyspnea. Due to the cost, uneven availability, and lack of experience with this therapy, the appropriate place for Heliox therapy in the symptomatic management of dyspnea remains unclear. &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Acupuncture",
"    </strong>",
"    &mdash; Acupuncture has been examined as a potential therapy to reduce dyspnea with mixed results in retrospective series and small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Two systematic reviews concluded that the evidence is inadequate to recommend acupuncture as a routine intervention for dyspnea control in terminally ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/46,86\">",
"     46,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104056\">",
"    <span class=\"h2\">",
"     Pharmacologic management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1646277\">",
"    <span class=\"h3\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid agonists are the most well-established pharmacologic treatment strategy for the symptomatic management of dyspnea in patients with advanced illness. Opioid receptors are found centrally (in respiratory control centers in the medulla oblongata) and peripherally (in airways and lung parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/87\">",
"     87",
"    </a>",
"    ]). Most hypotheses of opioid action for dyspnea (",
"    <a class=\"graphic graphic_table graphicRef80292 \" href=\"mobipreview.htm?8/10/8363\">",
"     table 8",
"    </a>",
"    ) focus on central pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404267\">",
"    <span class=\"h4\">",
"     Systemic opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from several randomized trials and at least four systematic reviews demonstrate the benefits of opioids in treating breathlessness; most of these trials enrolled patients with nonmalignant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/86,88-91\">",
"     86,88-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is the most widely-studied drug, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/92\">",
"     92",
"    </a>",
"    ], dihydrocodeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/93-96\">",
"     93-96",
"    </a>",
"    ], diamorphine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/97\">",
"     97",
"    </a>",
"    ] and oral transmucosal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/98\">",
"     98",
"    </a>",
"    ] have also been effective.",
"   </p>",
"   <p>",
"    Relatively small doses of opioids may suffice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/99\">",
"     99",
"    </a>",
"    ]. A phase II dose increment study to determine the minimum effective daily dose of opioids for dyspnea improvement and the durability of benefit was conducted in 85 patients, approximately one-half with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/100\">",
"     100",
"    </a>",
"    ]. Escalating doses of sustained-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    were administered, starting with 10 mg daily, and increasing by 10 mg a day to a maximum of 30 mg daily, if patients experienced less than a 10 percent reduction in dyspnea from their own baseline. For 70 percent of patients, the beneficial dose of sustained-release morphine was 10 mg daily, and the benefit at any dose was sustained for three months in 53 percent. &nbsp;",
"   </p>",
"   <p>",
"    The safety of opioids is relevant, given the potential for respiratory depression. Eleven of the eighteen studies included in the Cochrane review (some of which studied nebulized opioids) collected post-opioid blood gas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxygen saturation data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/101\">",
"     101",
"    </a>",
"    ]. No study detected a change in arterial oxygen saturation and only the study using dihydrocodeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/95\">",
"     95",
"    </a>",
"    ] identified an increase in arterial pCO",
"    <sub>",
"     2",
"    </sub>",
"    (in no patient rising above 40 mmHg). No studies have found excess mortality associated with the use of opioids for dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/89,102\">",
"     89,102",
"    </a>",
"    ]. As with use of opioids for pain relief, nausea, constipation and drowsiness are common adverse effects. Careful monitoring and individual dose titration are vital. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link&amp;anchor=H19097853#H19097853\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Palliative treatment of dyspnea'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As a result of these data, guidelines for management of dyspnea from all expert groups, including the American College of Chest Physicians, the American College of Physicians, the American Thoracic Society (ATS), and the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    all recommend the use of systemic opioids for relief of dyspnea in patients with advanced terminal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/49,52,62\">",
"     49,52,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2802076\">",
"     'Recommendations of expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1646299\">",
"    <span class=\"h4\">",
"     Nebulized opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nebulized opioids have limited systemic absorption, leading to the hypothesis that they may relieve dyspnea with fewer adverse effects than systemic administration. However, at present, the data are insufficient to justify use of any opioid by the inhaled route for relief of dyspnea. Systemic administration of opioids remains the treatment of choice to control dyspnea in terminally ill patients.",
"   </p>",
"   <p>",
"    A number of case reports and small series found symptomatic relief of dyspnea with the administration of different types of nebulized opioids, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. However, placebo-controlled trials have consistently demonstrated a lack of effect of nebulized morphine for dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/89,101,107,108\">",
"     89,101,107,108",
"    </a>",
"    ]. The only publication directly comparing nebulized versus systemic morphine for the treatment of dyspnea was too small to draw meaningful conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/109\">",
"     109",
"    </a>",
"    ]. A study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    (nebulized or systemic) versus placebo, adequately powered to detect a &ldquo;medium-large&rdquo; effect, found no difference between the three groups in dyspnea score 10 minutes posttreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/91\">",
"     91",
"    </a>",
"    ]. Nebulized fentanyl, which is lipophilic and thus more readily absorbed than morphine or hydromorphone, was superior to placebo for relief in dyspnea in patients with COPD in one small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1646736\">",
"    <span class=\"h3\">",
"     Promethazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;While small studies suggest a potential role for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    in the treatment of dyspnea (off-label), a class effect of phenothiazines for dyspnea has not been established.",
"   </p>",
"   <p>",
"    A randomized, crossover trial involving 15 patients with COPD found",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    superior to placebo for improvements in dyspnea score and exercise tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/111\">",
"     111",
"    </a>",
"    ]. In a separate randomized, crossover trial of seven patients with COPD, four treatment regimens were compared:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , morphine plus promethazine, morphine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/112\">",
"     112",
"    </a>",
"    ]. While no differences were found among the treatments for dyspnea scores, morphine plus promethazine was statistically superior to placebo for exercise tolerance. In contrast, a small randomized trial of promethazine versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    showed a favorable trend in the 12 minute walking test and ratings of subjective dyspnea in 11 patients with chronic airflow obstruction; however, the difference failed to reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104093\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of a small number of trials have concluded that the evidence does not support a role for benzodiazepines as a routine management strategy for dyspnea in the absence of anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/90,113\">",
"     90,113",
"    </a>",
"    ]. However, benzodiazepines are an important adjunct to therapy when anxiety, a common feature in dyspnea and especially severe dyspnea, is significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/114\">",
"     114",
"    </a>",
"    ]. The management of anxiety in patients with cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the systematic review concluded a lack of benefit to benzodiazepines, suboptimal dosing may have contributed to a lack of benefit in some studies. In the only trial to support benefit from a benzodiazepine alone over opioids, 63 patients with advanced cancer and severe dyspnea (mean score &gt;8.5 on a scale from 1 to 10) were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (starting dose 3 mg) or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    (starting dose 2 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/115\">",
"     115",
"    </a>",
"    ]. Doses were rapidly increased to an effective dose using a fast titration schedule over two hours, and patients were then followed daily for five days. Midazolam was superior to morphine in controlling both baseline and breakthrough dyspnea. The most common adverse event, which was not significantly more prevalent in either group, was mild somnolence which did not interfere with function. The short duration of observation and the severity of the dyspnea in this report raise questions as to the generalizability of the findings.",
"   </p>",
"   <p>",
"    Whether dyspnea is ameliorated by the addition of benzodiazepines to opioids remains uncertain. One trial evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    alone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    alone, or morphine plus midazolam for the treatment dyspnea in terminally ill cancer inpatients; there was no placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/116\">",
"     116",
"    </a>",
"    ]. Dyspnea scores among all groups were similar, but patients treated with midazolam in combination with morphine were more likely to report symptom relief and used fewer breakthrough doses than patients in the morphine group. The possibility that these beneficial effects were the result of midazolam&rsquo;s anxiolytic properties was not addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2623279\">",
"    <span class=\"h3\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large proportion of patients with terminal cancer and dyspnea have a history of smoking or chronic obstructive pulmonary disease (COPD). Assessment and management of potentially reversible airway obstruction is appropriate in all dyspneic cancer patients. The importance of this was illustrated in a study, which found that almost one-half of 57 patients with lung cancer had evidence of airflow obstruction, but only four were receiving appropriate bronchodilator therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/117\">",
"     117",
"    </a>",
"    ]. Although the study was small and observational, among those subsequently treated with bronchodilator therapy, at least one-half had a substantial reduction in dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Spirometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104100\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a lack of firm evidence to support benefit, systemic administration of loop diuretics may be beneficial to reduce lung congestion in dyspneic patients with end stage heart failure or lymphangitic carcinomatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=see_link&amp;anchor=H11#H11\">",
"     \"End of life considerations for heart failure patients\", section on 'Dyspnea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is insufficient evidence to recommend nebulized diuretics for the management of dyspnea in terminally ill patients. Nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    was evaluated as a symptomatic treatment for dyspnea in advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/118-121\">",
"     118-121",
"    </a>",
"    ]. A small randomized trial comparing nebulized furosemide, saline, or no treatment in 15 patients with cancer and breathlessness failed to demonstrate a beneficial effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4665213\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are not used for the palliation of dyspnea as a symptom. However, there are some settings in which they may effectively help to treat underlying causes of dyspnea: COPD exacerbations, tumor-related superior vena cava (SVC) syndrome in patients with glucocorticoid-responsive malignancies (eg, lymphoma, thymoma), tumor-related upper airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/123\">",
"     123",
"    </a>",
"    ], radiation pneumonitis, chemotherapy-induced pneumonitis, and pulmonary lymphangitic carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link&amp;anchor=H700934#H700934\">",
"     \"Malignancy-related superior vena cava syndrome\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link&amp;anchor=H26#H26\">",
"     \"Radiation-induced lung injury\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment\", section on 'Glucocorticoids'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20447283\">",
"    <span class=\"h3\">",
"     Palliative sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients at the end of life, dyspnea sometimes causes severe distress that cannot be relieved with standard measures. In such cases, the use of palliative sedation proportionate to relief of distress, including doses titrated to achieve unconsciousness if necessary, is an accepted strategy. Palliative sedation refers to use of a nonopioid drug to reduce a patient&rsquo;s awareness of refractory symptoms by decreasing their level of consciousness. Refractory symptoms are those that have been assessed and treated by an expert interdisciplinary team and have not responded to conventional symptom management. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"     \"Palliative sedation\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2802076\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the treatment of dyspnea in patients with advanced life threatening disease are available from the American Thoracic Society (ATS) (",
"    <a class=\"graphic graphic_table graphicRef72857 \" href=\"mobipreview.htm?14/30/14828\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/49\">",
"     49",
"    </a>",
"    ], American College of Chest Physicians (ACCP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/62,126\">",
"     62,126",
"    </a>",
"    ], American College of Physicians (ACP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/52\">",
"     52",
"    </a>",
"    ], and the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    . All recommend the use of systemic opioids for pharmacologic management of severe dyspnea.",
"   </p>",
"   <p>",
"    Guidelines from the ACCP, ACP, and",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend the use of supplemental oxygen for patients who are hypoxemic at rest or during minimal activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/52,62\">",
"     52,62",
"    </a>",
"    ]. Guidelines from",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    also support the use of temporary ventilatory support by NPPV if clinically indicated for a severe reversible condition, while the ATS guidelines on palliative care for patients with respiratory disease and critical illnesses suggest that NPPV may be appropriate when it is used for symptom relief in dying individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/60/30666/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89104107\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19978991\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspnea is a subjective experience of breathing discomfort or breathlessness that often affects patients with advanced life-threatening illness of all types. (See",
"      <a class=\"local\" href=\"#H3804717\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of a formal assessment of dyspnea in palliative care are to understand the intensity, distress, and functional impact of dyspnea, to diagnose potentially reversible contributing factors, and to monitor the response to interventions. Laboratory and radiological investigations are not helpful in detecting the presence or severity of dyspnea, but they may be helpful in determining etiology (",
"      <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H89104000\">",
"       'Assessment of dyspnea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937168\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpharmacologic interventions that may be of benefit include pulmonary rehabilitation (exercise training, breathing strategies such as pursed-lip breathing), ergonomics, and accommodation strategies, such as relaxation, modification of activity level, and use of a fan to blow air on the face. General steps to ameliorate the experience of dyspnea are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef74531 \" href=\"mobipreview.htm?37/34/38443\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H89104049\">",
"       'Nonpharmacologic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend oxygen for short term relief of hypoxemia in patients who are hypoxemic at rest or with minimal exertion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A trial of oxygen therapy should be performed to ascertain its effectiveness in that individual, as there are no identifiable factors that predict benefit. Oxygen has not been shown to relieve dyspnea in nonhypoxemic patients. (See",
"      <a class=\"local\" href=\"#H935678\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of noninvasive positive pressure ventilation (NPPV) in dyspneic patients at the end of life remains controversial because it generally requires initiation in hospital and may be life prolonging without necessarily improving quality of life. NPPV may be a reasonable choice for patients who otherwise require sedating doses of opioids to control dyspnea but wish to be as awake as possible, and for dying patients who wish to forestall death briefly for a specific goal. Before such treatment is initiated, the goals, timeframe for re-evaluation, criteria for continuation, and plan for eventual withdrawal of NPPV should be discussed. (See",
"      <a class=\"local\" href=\"#H935714\">",
"       'Noninvasive ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20446186\">",
"    <span class=\"h2\">",
"     Pharmacologic therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving palliative care who have distressing dyspnea, we recommend systemic opioids as the first-line agents (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Studies have not documented excess mortality associated with the use of opioids for dyspnea. However, careful monitoring and individual dose titration are vital to avoid respiratory depression and other side effects. (See",
"      <a class=\"local\" href=\"#H1646277\">",
"       'Opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against the use of nebulized opioids as compared to systemic opioid administration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), due to the lack of documented efficacy. (See",
"      <a class=\"local\" href=\"#H1646299\">",
"       'Nebulized opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with dyspnea that is refractory to opiates or accompanied by anxiety, benzodiazepines may be a useful adjunctive therapy. However, we suggest against the routine use of benzodiazepines in the palliative treatment of dyspnea (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H89104093\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      alone or in combination with opioids remains uncertain, and no class effect has been established. Promethazine should be used only as a second line agent or in combination with an opioid when further opioid dose titration is contraindicated. (See",
"      <a class=\"local\" href=\"#H1646736\">",
"       'Promethazine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchodilators, glucocorticoids, and diuretics may provide relief of dyspnea in certain clinical settings (",
"      <a class=\"graphic graphic_table graphicRef83934 \" href=\"mobipreview.htm?6/45/6878\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2623279\">",
"       'Bronchodilators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4665213\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H89104100\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at the end of life with severe dyspnea that cannot be relieved with standard measures, the use of palliative sedation proportionate to relief of distress, including doses titrated to achieve unconsciousness if necessary, is an accepted strategy. The indications for palliative sedation and its implementation are discussed separately. (See",
"      <a class=\"local\" href=\"#H20447283\">",
"       'Palliative sedation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link&amp;anchor=H29#H29\">",
"       \"Overview of managing common non-pain symptoms in palliative care\", section on 'Palliative sedation'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/1\">",
"      Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/2\">",
"      Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/3\">",
"      Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage 2010; 39:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/4\">",
"      Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/5\">",
"      Skilbeck J, Mott L, Page H, et al. Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med 1998; 12:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/6\">",
"      Roberts DK, Thorne SE, Pearson C. The experience of dyspnea in late-stage cancer. Patients' and nurses' perspectives. Cancer Nurs 1993; 16:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/7\">",
"      Gysels M, Bausewein C, Higginson IJ. Experiences of breathlessness: a systematic review of the qualitative literature. Palliat Support Care 2007; 5:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/8\">",
"      Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 1999; 354:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/9\">",
"      Fainsinger RL, Waller A, Bercovici M, et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000; 14:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/10\">",
"      Mercadante S, Porzio G, Valle A, et al. Palliative sedation in patients with advanced cancer followed at home: a systematic review. J Pain Symptom Manage 2011; 41:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/11\">",
"      Brown ML, Carrieri V, Dodd MJ. Lung cancer and dyspnea: the patient's perception. Oncol Nurs Forum 1986; 13:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/12\">",
"      Nicolson P, Anderson P. The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/13\">",
"      Barnett M. Chronic obstructive pulmonary disease: a phenomenological study of patients' experiences. J Clin Nurs 2005; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/14\">",
"      Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23:6240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/15\">",
"      Vigan&ograve; A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 2000; 14:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/16\">",
"      Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/17\">",
"      Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/18\">",
"      Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 2012; 84:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/19\">",
"      Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/20\">",
"      Mularski RA, Campbell ML, Asch SM, et al. A review of quality of care evaluation for the palliation of dyspnea. Am J Respir Crit Care Med 2010; 181:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/21\">",
"      Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the clinical rather than the research setting. Curr Opin Support Palliat Care 2008; 2:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/22\">",
"      Simon PM, Schwartzstein RM, Weiss JW, et al. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142:1009.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartzstein RM. Language of dyspnea. In: Dyspnea; Mechanisms, measurement and management, 2nd, Mahler DA, O&rsquo;Donnell DE (Eds), Taylor &amp; Francis Group, Boca Raton, FL 2005. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/24\">",
"      Harver A, Mahler DA, Schwartzstein RM. Use of a descriptor model for prospective diagnosis of dyspnea. Am J Respir Crit Care Med 2000; 161:A705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/25\">",
"      Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/26\">",
"      McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J 1978; 2:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/27\">",
"      O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care (Engl) 1999; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/28\">",
"      Bailey PH. Death stories: acute exacerbations of chronic obstructive pulmonary disease. Qual Health Res 2001; 11:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/29\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/30\">",
"      Campbell ML. Psychometric testing of a respiratory distress observation scale. J Palliat Med 2008; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/31\">",
"      Uronis HE, Shelby RA, Currow DC, et al. Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. J Pain Symptom Manage 2012; 44:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/32\">",
"      Reddy SK, Parsons HA, Elsayem A, et al. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 2009; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     Heyse-Moore LH. On Dyspnea in Advanced Cancer, Southampton University, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/34\">",
"      Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998; 16:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/35\">",
"      Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage 2001; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/36\">",
"      Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/37\">",
"      Tanaka K, Akechi T, Okuyama T, et al. Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? J Pain Symptom Manage 2002; 23:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/38\">",
"      Gift AG, Plaut SM, Jacox A. Psychologic and physiologic factors related to dyspnea in subjects with chronic obstructive pulmonary disease. Heart Lung 1986; 15:595.",
"     </a>",
"    </li>",
"    <li>",
"     Carrieri-Kohlman, V. Non-pharmacologic approaches. In: Dyspnoea in advanced disease: A guide to clinical management, Booth, S, Dudgeon, D (Eds), Oxford University Press, New York 2006. p.171.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/40\">",
"      Zhao I, Yates P. Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliat Med 2008; 22:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/41\">",
"      Bredin M, Corner J, Krishnasamy M, et al. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ 1999; 318:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/42\">",
"      Schwartzstein RM, Lahive K, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987; 136:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/43\">",
"      Bausewein C, Booth S, Gysels M, et al. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. BMC Palliat Care 2010; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/44\">",
"      Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010; 39:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/45\">",
"      Thomas JR, von Gunten CF. Clinical management of dyspnoea. Lancet Oncol 2002; 3:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/46\">",
"      Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; :CD005623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/47\">",
"      Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; :CD003793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/48\">",
"      Puhan M, Scharplatz M, Troosters T, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; :CD005305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/49\">",
"      Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/50\">",
"      Riesenberg H, L&uuml;bbe AS. In-patient rehabilitation of lung cancer patients--a prospective study. Support Care Cancer 2010; 18:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/51\">",
"      Davidson PM, Johnson MJ. Update on the role of palliative oxygen. Curr Opin Support Palliat Care 2011; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/52\">",
"      Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/53\">",
"      Lorenz KA, Lynn J, Dy SM, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med 2008; 148:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/54\">",
"      Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev 2008; :CD004769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/55\">",
"      Booth S, Kelly MJ, Cox NP, et al. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 1996; 153:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/56\">",
"      Ahmedzai SH, Laude E, Robertson A, et al. A double-blind, randomised, controlled Phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. Br J Cancer 2004; 90:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/57\">",
"      Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/58\">",
"      Chua TP, Ponikowski PP, Harrington D, et al. Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. Heart 1996; 76:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/59\">",
"      Moore DP, Weston AR, Hughes JM, et al. Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet 1992; 339:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/60\">",
"      Restrick LJ, Davies SW, Noone L, Wedzicha JA. Ambulatory oxygen in chronic heart failure. Lancet 1992; 340:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/61\">",
"      Jones DJ, Paul EA, Bell JH, Wedzicha JA. Ambulatory oxygen therapy in stable kyphoscoliosis. Eur Respir J 1995; 8:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/62\">",
"      Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010; 137:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/63\">",
"      Philip J, Gold M, Milner A, et al. A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage 2006; 32:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/64\">",
"      Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage 1992; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/65\">",
"      Swinburn CR, Mould H, Stone TN, et al. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis 1991; 143:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/66\">",
"      Alvisi V, Mirkovic T, Nesme P, et al. Acute effects of hyperoxia on dyspnea in hypoxemia patients with chronic airway obstruction at rest. Chest 2003; 123:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/67\">",
"      Liss HP, Grant BJ. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/68\">",
"      Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010; 376:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/69\">",
"      Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/70\">",
"      Yeow ME, Mehta RS, White DB, Szmuilowicz E. Using noninvasive ventilation at the end of life #230. J Palliat Med 2010; 13:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/71\">",
"      Freichels TA. Palliative ventilatory support: use of noninvasive positive pressure ventilation in terminal respiratory insufficiency. Am J Crit Care 1994; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/72\">",
"      Azoulay E, Kouatchet A, Jaber S, et al. Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Med 2013; 39:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/73\">",
"      Sinuff T, Cook DJ, Keenan SP, et al. Noninvasive ventilation for acute respiratory failure near the end of life. Crit Care Med 2008; 36:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/74\">",
"      Ehlenbach WJ, Curtis JR. Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know? Crit Care Med 2008; 36:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/75\">",
"      Nava S, Ferrer M, Esquinas A, et al. Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial. Lancet Oncol 2013; 14:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/76\">",
"      Levy M, Tanios MA, Nelson D, et al. Outcomes of patients with do-not-intubate orders treated with noninvasive ventilation. Crit Care Med 2004; 32:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/77\">",
"      Schettino G, Altobelli N, Kacmarek RM. Noninvasive positive pressure ventilation reverses acute respiratory failure in select \"do-not-intubate\" patients. Crit Care Med 2005; 33:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/78\">",
"      Yeow ME, Szmuilowicz E. Practical aspects of using noninvasive positive pressure ventilation at the end of life #231. J Palliat Med 2010; 13:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/79\">",
"      Murgu S, Langer S, Colt H. Bronchoscopic intervention obviates the need for continued mechanical ventilation in patients with airway obstruction and respiratory failure from inoperable non-small-cell lung cancer. Respiration 2012; 84:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/80\">",
"      Bandyopadhyay D, Induru RR. Role of palliative tracheobronchial stenting in hospice patients: boon or bane? Am J Hosp Palliat Care 2011; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/81\">",
"      Laude EA, Duffy NC, Baveystock C, et al. The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med 2006; 173:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/82\">",
"      Chiappa GR, Queiroga F Jr, Meda E, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/83\">",
"      D'Angelo E, Santus P, Civitillo MF, et al. Expiratory flow-limitation and heliox breathing in resting and exercising COPD patients. Respir Physiol Neurobiol 2009; 169:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/84\">",
"      Lewith GT, Prescott P, Davis CL. Can a standardized acupuncture technique palliate disabling breathlessness: a single-blind, placebo-controlled crossover study. Chest 2004; 125:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/85\">",
"      Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for the relief of cancer-related breathlessness. Palliat Med 1996; 10:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/86\">",
"      Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008; 26:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/87\">",
"      Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 2000; 66:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/88\">",
"      Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/89\">",
"      Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nat Clin Pract Oncol 2008; 5:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/90\">",
"      Viola R, Kiteley C, Lloyd NS, et al. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer 2008; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/91\">",
"      Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008; 36:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/92\">",
"      Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987; 81:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/93\">",
"      Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in \"pink puffers\". Br Med J (Clin Res Ed) 1983; 286:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/94\">",
"      Chua TP, Harrington D, Ponikowski P, et al. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/95\">",
"      Bar-Or D, Marx JA, Good J. Breathlessness, alcohol, and opiates. N Engl J Med 1982; 306:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/96\">",
"      Woodcock AA, Gross ER, Gellert A, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/97\">",
"      Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the \"pink puffer\" syndrome. Eur Respir J 1991; 4:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/98\">",
"      Gauna AA, Kang SK, Triano ML, et al. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. J Palliat Med 2008; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/99\">",
"      Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009; 64:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/100\">",
"      Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/101\">",
"      Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001; :CD002066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/102\">",
"      Hallenbeck J. Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death? J Palliat Med 2012; 15:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/103\">",
"      Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med 1997; 11:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/104\">",
"      Coyne P, Viswanathan R, Smith TJ. Fentanyl by nebulizer reduces dyspnea (abstract). Proc Am Soc Clin Oncol 2001; 20:402a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/105\">",
"      Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/106\">",
"      Sarhill N, Walsh D, Khawam E, et al. Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care 2000; 17:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/107\">",
"      Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev 2002; :CD002872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/108\">",
"      Davis C. The role of nebulised drugs in palliating respiratory symptoms from mlaignant disease. Eur J Palliat Care 1995; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/109\">",
"      Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 2005; 29:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/110\">",
"      Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage 2012; 43:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/111\">",
"      Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J (Clin Res Ed) 1981; 283:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/112\">",
"      Light RW, Stansbury DW, Webster JS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest 1996; 109:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/113\">",
"      Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010; :CD007354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/114\">",
"      Clemens KE, Klaschik E. Dyspnoea associated with anxiety--symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients. Support Care Cancer 2011; 19:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/115\">",
"      Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010; 39:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/116\">",
"      Navigante AH, Cerchietti LC, Castro MA, et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006; 31:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/117\">",
"      Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 1995; 89:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/118\">",
"      Newton PJ, Davidson PM, Macdonald P, et al. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008; 36:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/119\">",
"      Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/120\">",
"      Kohara H, Ueoka H, Aoe K, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003; 26:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/121\">",
"      Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/122\">",
"      Wilcock A, Walton A, Manderson C, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008; 63:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/123\">",
"      Elsayem A, Bruera E. High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway. Support Care Cancer 2007; 15:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/124\">",
"      Storck K, Crispens M, Brader K. Squamous cell carcinoma of the cervix presenting as lymphangitic carcinomatosis: a case report and review of the literature. Gynecol Oncol 2004; 94:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/60/30666/abstract/125\">",
"      Lin RJ, Adelman RD, Mehta SS. Dyspnea in palliative care: expanding the role of corticosteroids. J Palliat Med 2012; 15:834.",
"     </a>",
"    </li>",
"    <li>",
"     Consensus statement on the management of dyspnea in patients with advanced lung or heart disease from the American College of Chest Physicians available online at file://www.chestnet.org/accp/consensus-statements/american-college-chest-physicians-consensus-statement-management-dyspnea-patien (Accessed on March 23, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14238 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30666=[""].join("\n");
var outline_f29_60_30666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H89104107\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89103965\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3804717\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89103972\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89103979\">",
"      Psychological and social impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89103986\">",
"      Prognostic significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89103993\">",
"      PATHOPHYSIOLOGY AND CAUSES OF DYSPNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89104000\">",
"      ASSESSMENT OF DYSPNEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104007\">",
"      Quality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104014\">",
"      Intensity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104021\">",
"      Functional impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104028\">",
"      Distress caused by dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31015989\">",
"      Dyspnea and psychological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104035\">",
"      Role of investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89104042\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104049\">",
"      Nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5404055\">",
"      - General measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935168\">",
"      - Pulmonary rehabilitation and respiratory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935678\">",
"      - Oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H935686\">",
"      Patients with hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H935693\">",
"      Non-hypoxemic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935714\">",
"      - Noninvasive ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H935721\">",
"      - Airway debulking and stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5403980\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89104056\">",
"      Pharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1646277\">",
"      - Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5404267\">",
"      Systemic opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1646299\">",
"      Nebulized opioids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1646736\">",
"      - Promethazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89104093\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2623279\">",
"      - Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89104100\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4665213\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20447283\">",
"      - Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2802076\">",
"      RECOMMENDATIONS OF EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89104107\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19978991\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H937168\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20446186\">",
"      Pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/14238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14238|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/45/35537\" title=\"figure 1\">",
"      Symptoms in the last six months of life in cancer patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/13/23762\" title=\"figure 2\">",
"      Memorial symptom assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/31/44542\" title=\"figure 3\">",
"      The Oxygen Cost Diagram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/5/42076\" title=\"table 1\">",
"      Prevalence of dyspnea in advanced illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/45/6878\" title=\"table 2\">",
"      Causes of dyspnea in palliative care and potential treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26299\" title=\"table 3\">",
"      Domains ESAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/10/15532\" title=\"table 4\">",
"      Borg scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/34/38443\" title=\"table 5\">",
"      Appr treat dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/5/11358\" title=\"table 6\">",
"      Studies of supplemental oxygen for dyspnea in advanced cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/45/4827\" title=\"table 7\">",
"      Mech supple oxy may red dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/10/8363\" title=\"table 8\">",
"      Mech opioids may red dys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/30/14828\" title=\"table 9\">",
"      ATS Dyspnea Treatment Guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./palliative-sedation?source=related_link\">",
"      Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8839?source=related_link\">",
"      Physiology of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13993?source=related_link\">",
"      Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./survival-estimates-in-advanced-terminal-cancer?source=related_link\">",
"      Survival estimates in advanced terminal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=related_link\">",
"      Symptom-based management of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_60_30667="Common tremors";
var content_f29_60_30667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common tremors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Resting tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinsonian syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Midbrain (rubral) tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wilson's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe essential tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Postural-action tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enhanced physiologic tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Essential tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary writing tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Other extrapyramidal disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wilson's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebellar disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peripheral neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Intention tremor (cerebellar outflow)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebellar disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple sclerosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Midbrain stroke",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Midbrain trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30667=[""].join("\n");
var outline_f29_60_30667=null;
var title_f29_60_30668="Presentations thrombocytopenia";
var content_f29_60_30668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common presentations of patients with thrombocytopenia to primary care physicians",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Office presentation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Asymptomatic, ISOLATED, incidentally-discovered thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Pseudothrombocytopenia, laboratory error",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Drug-induced thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Idiopathic thrombocytopenic purpura (ITP)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Pregnancy: gestational thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Less common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Occult liver disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Myelodysplastic syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Congenital thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       HIV infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Symptomatic, severe thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Drug-induced thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Idiopathic thrombocytopenic purpura (ITP)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hospital presentation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Thrombocytopenia as part of a multisystem illness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Drug-induced thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Heparin-induced thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Liver disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Sepsis with disseminated intravascular coagulation (DIC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cancer with disseminated intravascular coagulation (DIC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       Pregnancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Preeclampsia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Abruptio placentae with disseminated intravascular coagulation (DIC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Multi-organ failure syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Less common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30668=[""].join("\n");
var outline_f29_60_30668=null;
var title_f29_60_30669="Metab conseq bowel segment";
var content_f29_60_30669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary indications and metabolic consequences for use of bowel segments",
"    <sup>",
"     [1-17]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bowel segment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolic consequences",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric",
"       </td>",
"       <td>",
"        <p>",
"         Children requiring diversion (extrophy, pelvic radiation)",
"        </p>",
"        <p>",
"         Renal insufficiency",
"        </p>",
"       </td>",
"       <td>",
"        Metabolic alkalosis (&darr; K, &darr; Cl, hypergastrinemia)",
"       </td>",
"       <td>",
"        <p>",
"         Hematuria-dysuria syndrome",
"        </p>",
"        <p>",
"         Dehydration, lethargy, seizures, respiratory distress",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jejunum",
"       </td>",
"       <td>",
"        <p>",
"         Pelvic radiation",
"        </p>",
"        <p>",
"         Deficient ureteral length",
"        </p>",
"        <p>",
"         Compromised viability of other small or large bowel",
"        </p>",
"       </td>",
"       <td>",
"        Metabolic acidosis (&darr; Na, &darr; Cl, &uarr; K, azotemia)",
"       </td>",
"       <td>",
"        Dehydration, nausea/vomiting, weakness, lethargy, seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ileum or ileal-colic reservoirs",
"       </td>",
"       <td>",
"        <p>",
"         Malignancies requiring removal of the bladder",
"        </p>",
"        <p>",
"         Severe hemorrhagic cystitis",
"        </p>",
"        <p>",
"         Incontinence",
"        </p>",
"       </td>",
"       <td>",
"        Metabolic acidosis (&uarr; Cl, &darr; bicarbonate, azotemia)",
"       </td>",
"       <td>",
"        <p>",
"         Fatigue, anorexia, weight loss, diarrhea, polydipsia",
"        </p>",
"        <p>",
"         B",
"         <sub>",
"          12",
"         </sub>",
"         and fat soluble vitamin deficiency",
"        </p>",
"        <p>",
"         Diarrhea, urinary calculi, cholelithiasis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon (ureterosigmoidostomy)",
"       </td>",
"       <td>",
"        <p>",
"         Children requiring diversion (extrophy, pelvic radiation)",
"        </p>",
"        <p>",
"         No other bowel segment alternative",
"        </p>",
"       </td>",
"       <td>",
"        Metabolic acidosis (&uarr; Cl, &darr; bicarbonate, azotemia)",
"       </td>",
"       <td>",
"        <p>",
"         Fatigue, anorexia, weight loss, diarrhea, polydipsia",
"        </p>",
"        <p>",
"         Pyelonephritis",
"        </p>",
"        <p>",
"         Adenocarcinoma at anastomotic site",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse colon conduit",
"       </td>",
"       <td>",
"        <p>",
"         Malignancies requiring removal of the bladder",
"        </p>",
"        <p>",
"         Small bowel not practical",
"        </p>",
"       </td>",
"       <td>",
"        Metabolic acidosis (&uarr; Cl, &darr; bicarbonate, azotemia)",
"       </td>",
"       <td>",
"        <p>",
"         Fatigue, anorexia, weight loss, diarrhea, polydipsia",
"        </p>",
"        <p>",
"         Pyelonephritis",
"        </p>",
"        <p>",
"         Adenocarcinoma at anastomotic site",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     K: potassium; Cl: chloride; &darr;: decreased; &uarr;: increased.",
"    </div>",
"    <div class=\"reference\">",
"     1. Adams, MC, Mitchell, ME, Rink, RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol 1988; 140:1152.",
"     <br>",
"      2. Kaveggia, FF, Thompson, JS, Schafer, EC, et al. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990; 150:2389.",
"      <br>",
"       3. McDougal, WS, Koch, MO. Accurate determination of renal function in patients with intestinal urinary diversions. J Urol 1986; 135:1175.",
"       <br>",
"        4. Koch, MO, McDougal, WS, Flora, MD. Urease and the acidosis of urinary intestinal diversion. J Urol 1991; 146:458.",
"        <br>",
"         5. Koch, MO, McDougal, WS, Thompson, CO. Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study with rats. J Urol 1991; 146:1390.",
"         <br>",
"          6. Klein, EA, Montie, JE, Montague, DK, et al. Jejunal conduit urinary diversion. J Urol 1986; 135:244.",
"          <br>",
"           7. Plawker, MW, Rabinowitz, SS, Etwaru, DJ, Glassberg, KI. Hypergastrinemia, dysuria-hematuria and metabolic alkalosis: complications associated with gastrocystoplasty. J Urol 1995; 154:546.",
"           <br>",
"            8. Nguyen, DH, Bain, MA, Salmonson, KL, et al. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993; 150:707.",
"            <br>",
"             9. Gosalbez, R Jr, Woodard, JR, Broecker, BH, Warshaw, B. Metabolic complications of the use of stomach for urinary reconstruction. J Urol 1993; 150:710.",
"             <br>",
"              10. Filipsson, S, Hulten, L, Lindstedt, G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978; 13:529.",
"              <br>",
"               11. Thompson, WG, Wrathell, E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977; 20:461.",
"               <br>",
"                12. Koch, MO, McDougal, WS. Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments. J Urol 1985; 134:165.",
"                <br>",
"                 13. Boyd, SD, Schiff, WM, Skinner, DG, et al. Prospective study of metabolic abnormalities in patient with continent Kock pouch urinary diversion. Urology 1989; 33:85.",
"                 <br>",
"                  14. Koch, MO, Gurevitch, E, Hill, DE, McDougal, WS. Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. J Urol 1990; 143:1275.",
"                  <br>",
"                   15. Mills, R. D., Studer, U. E.: Metabolic consequences of continent urinary diversion. J Urol 1999; 161:1057.",
"                   <br>",
"                    16. Stampfer, DS, McDougal, WS, McGovern, FJ. The use of in bowel urology. Metabolic and nutritional complications. Urol Clin North Am 1997; 24:715.",
"                    <br>",
"                     17. McDougal, WS, Stampfer, DS, Kirley, S, et al. Intestinal ammonium transport by ammonium and hydrogen exchange. J Am Coll Surg 1995; 181:241.",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30669=[""].join("\n");
var outline_f29_60_30669=null;
var title_f29_60_30670="Structure T cell receptor";
var content_f29_60_30670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    The structure of the T cell receptor (TCR)/CD3 complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The TCR is made up of two disulfide-linked chains, alpha and beta, (or gamma and delta); the CD3 complex consists of five polypeptides, one each of gamma and delta, two of epsilon, and a disulfide-linked homodimer of two zeta chains [zeta]",
"    <sub>",
"     2",
"    </sub>",
"    , or a heterodimer of zeta and eta (shown here). The carboxyl termini of these proteins are intracytoplasmic. ZAP-70 and fyn are tyrosine kinases important in T cell activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30670=[""].join("\n");
var outline_f29_60_30670=null;
var title_f29_60_30671="Cannulation following precut";
var content_f29_60_30671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sphinterome insertion with guidewire assistance to complete precut sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once access has been gained, a standard guidewire and papilltome can be used to complete the sphincterotomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas A Howell, MD and David J Desilets, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_60_30671=[""].join("\n");
var outline_f29_60_30671=null;
